Clinical Development -General Medicine
Secukinumab/AIN457
Clinical Trial Protocol CAIN457A2310 / [STUDY_ID_REMOVED]
A randomized, double- blind, placebo - and activ e controlled 
multicenter trial to demonstrate efficacy of subcutaneous 
secukinumab compared to placebo and etanercept (in a 
single -blinded arm) after tw elve w eeks of treatment, and to 
assess the safety, tolerability , and long -term efficacy in 
subjects from 6 to less than 18 y ears of age w ith se vere 
chronic plaque psoriasis
Document type: Amended Protocol Version 
EUDRACT number: 2014 -005663 -32
Version number: v04 (clean )
Development phase: III
Release date: 18-Sep-2020
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed 
without the consent of [COMPANY_001]
Clinical Trial Protocol Template Version 2.0, November, 2013

[COMPANY_001] Confidential Page 2
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Table of contents
Table of contents ................................................................................................................. [ADDRESS_136875] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Amendment 4 (18 -
Sep-2020) ............................................................................................ 11
Amendment 3 .................................................................................................................... 14
Amendment 2 .................................................................................................................... 15
Amendment 1 .................................................................................................................... 17
Protocol summary .............................................................................................................. 18
1Introduction ................................ ................................ ................................ ....................... 21
1.1 Background ............................................................................................................ 21
1.2 Purpose .................................................................................................................. 23
2Study  objectives ................................................................................................................. 24
2.1 Primary  objective(s) ............................................................................................... 24
2.2 Secondary  objectives ............................................................................................. 24
24
3Investigational plan ........................................................................................................... 25
3.1 Study  design ........................................................................................................... 25
3.2 Rationale of study  design ....................................................................................... 29
3.3
Rationale of dose/regimen, route of administration and duration of treatment .....29
3.4 Rationale fo r choice of comparator ....................................................................... 30
3.5 Purpose and timing of interim anal yses/design adaptations .................................. [ADDRESS_136876] ................................................................................................ 41

[COMPANY_001] Confidential Page 3
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
5.5.[ADDRESS_136877] demographics/other baseline charac teristics ............................................. 64
6.2.1 Demographics ....................................................................................... 64
6.2.2 Psoriasis medical history / 
Previous psoriasis therapy.......................... 64
6.2.3 Relevant medical history / current medical conditions......................... [ADDRESS_136878] X -ray (optional)........................................................................... 65
6.2.5 Determination of Tuberculosis status
.................................................... 65
6.2.6 Other baseline characteristics ................................................................ 68
6.3 Treatment exposure and compliance ..................................................................... 68
6.4 Efficacy .................................................................................................................. 68
6.4.1 Investigator Global assessment (IGA mod 2011) ................................. 68
6.4.2 Assessment of total body surface area (B SA) and psoriasis area 
safet y index (PASI
) ............................................................................... 69
72
6.4.4 Appropriateness of efficacy  assessments .............................................. 72
6.5 Safety ..................................................................................................................... 72
6.5.1 Physical examination ............................................................................ 72
73
6.5.3 Vital signs .............................................................................................. 73
6.5.4 Height and weight ................................................................................. 73
6.5.5 Laboratory  evaluations .......................................................................... 74

[COMPANY_001] Confidential Page 4
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.5.6 Electrocardiogram (ECG) ..................................................................... [ADDRESS_136879] demographics and other baseline characteristics...................................... 92
9.3 Treatments ............................................................................................................. 93
9.4 Analy sis of the primary  variable(s) ....................................................................... 93
9.4.1 Variable(s) ............................................................................................. 93
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 93
9.4.3 Handling of missing values/censo ring/discontinuations ....................... 94
9.4.4 Supportive analy ses............................................................................... 95
9.5 Analy sis of seco
ndary  variables ............................................................................ 95
9.5.1 Efficacy  variables
.................................................................................. 95
9.5.2 Other Efficacy  variables........................................................................ 96
9.5.3 Safety
 variables ..................................................................................... 97

[COMPANY_001] Confidential Page 5
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
9.5.4 Resource utilization ............................................................................... 99
9.5.5 Health
-related Quality  of L ife............................................................... 99
100
100
9.5.8 Biomarkers .......................................................................................... 100
9.5.9 PK/PD ................................................................................................. 100
9.6 Interim anal yses................................................................................................... 100
9.7
Sample size calculation........................................................................................ 101
10Ethical considerations ...................................................................................................... 102
10.1 Regulatory
 and ethical compliance ...................................................................... 102
10.2 Informed consent procedures
............................................................................... 102
10.3 Responsibilities of the investigator and IRB/ IEC................................................ 103
10.4 Publication of study  protocol and results ............................................................. 104
11Protocol adherence ................................ ................................ ................................ .......... 104
11.1 Protocol Amendments ......................................................................................... 104
12References ....................................................................................................................... 104
13Appendix 1: Clinically  notable laboratory  values and vital signs ................................... 107
14Appendix 2: L iver event a nd Laboratory  trigger Definitions and Follow
-up 
Requirements ................................................................................................................... 110
112
16
Appendix 4: Weight and recommended blood volumes ................................................. 113
114
18Appendix 6:  CDL QI questionnaire ................................................................................ 115
19
Appendix 7: CHAQ Questionnaire ................................................................................. 117

[COMPANY_001] Confidential Page 6
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
List of tables
Table 5-1 Secuk inumab/Placebo treatment arms and injections at each visit 
during Induction and maintenance epoch ............................................. 37
Table 5
-2 Prohibited treatment .............................................................................. 49
Table 6
-1 Visit and assessment schedule for the Blinded Epoch.......................... 56
Table 6-2 Visit and Assessment schedule for the Extended treatment epoch .......60
Table 6-3 IGA mod 2011 s cale.............................................................................. 69
Table 6
-4 PASI  scoring s ystem............................................................................. 70
Table 7
-1 Specific Renal Alert C riteria and Actions ............................................. 88
Table 9
-1 Treatment groups for analy ses.............................................................. 91
Table 13
-1 Notable Pediatric ranges for vital signs* ............................................ 109
Table 13
-2 Recommended Dimensions for Blood Pressure Cuff Bladders .......... 109
Table 14-1 Liver Event and Laboratory  Trigger Definitions ................................ 110
Table 14-2 Follow Up Requirements for L iver Events and Laboratory  Triggers .110
112
112
Table 16-1 Total blood volume, 1% and 3% of total blood volume by  [CONTACT_121906] 85mL per kg total blood volume ......................................... [ADDRESS_136880] of figures
Figure 3 -
1 Study  design ................................ ................................ .......................... 26
Figure 3 -2 Average concentration for the proposed low dose and high dose 
secukinumab arms ................................................................................. 30
Figure 6 -
1 Tuberculosis screening flowchart ......................................................... 67
Figure 9 -
1 Testing strategy ..................................................................................... 96

[COMPANY_001] Confidential Page 7
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
List of abbreviations
AE adverse event
ACR American college of Rheumatology
ALT alanine aminotransferase
ANCOVA Analysis of covariance
AST aspartate aminotransferase
BDR Bioanalytical Data Report
b.i.d. twice a day
BUN Blood Urea Nitrogen
CFR US Code of Federal Regulations
CDLQI Children’s Dermatology Life Quality Index
CHAQ© Childhood Health Assessment Questionnaire
COVID -19 Coronavirus d isease of 2019
CRF Case Report/Record Form (paper or electronic)
CPO Countr y Pharma Organization
CRO Contract Research Organization
CS Corticosteroids
CT Computerized Tomography
CTC Comm on Toxicity Criteria
DLQI Dermatology Life Quality Index
DMC Data Monitoring Board
DNA Deoxyribonucleic acid
DS&E Drug Safety & Epi[INVESTIGATOR_121862]
e.g. Example
EOI End of Induction
EOM End of Maintenance
EOT End of Treatment
EOF End of Follow up
eCRF electronic Case Report/Record Form
EDC Electronic Data Capture
EDTA Ethylenediaminetetraacetic acid
ELISA Enzy me-Linked Immunosorbent Assay
eGFR Estimated Glomerular Filtration Rate
EU European Union
FAS Full Analysis Set

[COMPANY_001] Confidential Page 8
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
FDA [LOCATION_002] F ood and Drug Administration
GCP Good Clinical Practice
GDPR General Data Protection Regulation
GGT Gamma –glutam yl transferase
GTD Global Trial Director
GWA genom e-wide association
HA Health Authorities
hCG Human chorionic gonadotropin
HCP Health Care Professional
HRQoL health- related quality of life
HIV Human Immunodeficiency virus
IA Interim Analysis 
IB Investigator’s Brochure
ICH International Council for Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
ICF Informed Consent Form
IEC Independent Ethics Committee
IGA Investigator’s Global Assessment
IGA mod 2011 [COMPANY_001] Investigator’s Global Assessment modified [ADDRESS_136881] (raised serum transaminases and/or bilirubin levels)
LLOQ lower limit of quantification
MACE Major Adverse Cardiovascular events
MAP Meta -Analytic -Prediction
MedDRA Medical dictionary for regulatory activities 

[COMPANY_001] Confidential Page 9
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
MRI Magnetic Resonance Imaging
OC/RDC Orac le Clinical/Remote Data Capture
o.d. once a day
 
p.o. oral(ly)
PASI Psoriasis Area and Severity Index
PCR Protein over Creatinine Ratio
PFS Pre-filled Syringe  
PRO Patient Reported Outcome
PT/INR Prothrombin Time/International Normalized Ratio
PUVA Photo chemotherapy (e.g. psoralen + UVA treatment)
QFT QuantiFERON TB -Gold test
R Randomization
RDC Remote Data Capture
SAE serious adverse event
s.c. Subcutaneous
SGOT Serum Glutamic Oxaloacetic Transaminase
SGPT Serum Glutamic Py ruvic Transaminase
SMQ Standardized MedDRA queries
SST Serum Separator Tube
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
TB tuberculosis
TBL Total Bilirubin
TCS Topi[INVESTIGATOR_121863]17 T helper [ADDRESS_136882] 400 nm–[ADDRESS_136883] 315 nm–280 nm
VAS Visual Analog Scale
vs Versus
WBC White blood cells / leukocy tes
WHO World Health Organization

[COMPANY_001] Confidential Page 10
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_37214] A group of newly enrolled patients treated at a specific dose and regimen 
(i.e. treatment group) at the same time
Control drug Any drug (an active drug or an inactive drug, such as a placebo) which is 
used as a comparator to the drug being tested in the trial
Dose level The dose of drug given to the patient (total daily or weekly etc.)
Enrollment Point/time of patient entry into the study at which informed consent must 
be obtained (i.e. prior to starting any of the procedur es described in the 
protocol)
Epoch A portion of the study which serves a specific purpose. Typi[INVESTIGATOR_121864]: screening/recruitment, wash -out, treatment, and follow-up
Investigational drug The drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug” or “investigational medicinal product.”
Investigational treatment All investigational drug(s) whose properties are being tested in the study 
as well as their associated treatment controls. 
This includes any placebos, any active controls, as well as approved 
drugs used outside of their indication/approved dosage or tested in a fixed 
combination. 
Investigational treatment generally does not include proto col-specified 
concomitant background therapi[INVESTIGATOR_121865] .
Medication number A unique identifier on the label of each investigational/study drug package 
in studies that dispense medication using an IRT system .
Personal Data Subject information collected by [CONTACT_5336]. This data includes subject 
identifier information, study information and biological samples.
Protocol A written account o f all the procedures to be followed in a trial, which 
describes all the administrative, documentation, analytical and clinical 
processes used in the trial.
Premature subject/patient 
withdrawalPoint/time when the patient exits from the study prior to the planned 
completion of all study treatment administration and/or assessments; at 
this time all study treatment administration is discontinued and no further 
assessments are planned, unless the patient will be followed for 
progression and/or survival
Random ization number A unique identifier assigned to each randomized patient, corresponding to 
a specific treatment arm assignment
Study drug/ treatment Any single drug or combination of drugs administered to the patient as 
part of the required study procedures; includes investigational drug (s), 
active drug run -ins or background therapy 
Study/investigational treatment 
discontinuationPoint/time when pat ient permanently stops taking study/investigational 
treatment  for any reason; may or may not also be the point/time of 
premature patient withdrawal
Subject Number A number assigned to each patient who enrolls into the study 
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of study consent Withdrawal of consent from the study occurs only when a subject does not 
want to participa te in the study any longer, and does not allow any further 
collection of personal data.

[COMPANY_001] Confidential Page 11
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Amendment 4 (18-Sep -2020)
The rationale for thisamendment is to introduce a level of flexibility  in drug dispensation, 
protocol assessment sand visit schedule if a major health care event like COVID -19 
(Coronavirus disease of 2019) pandemic requires it, thus allowing patients to remain in the trial 
andcontinue treatment while being monitored for safet y.
The purpose of these changes, is to reduce the risk of exposure for patients and site staff and 
potentially  the risk of transmission of infe ctious diseases (e.g. COVID -19).
These changes are limited to the duration of COVID -[ADDRESS_136884] be done in accordance with the 
local rules and regulations relevant to 
pandemic containment measures.
In addition, renal and liver monitoring procedures will no longer be followed for subjects who 
reach adulthood ( ≥18 years). These procedures were introduced for the pediatric population in
this study  but are no longer relevant once subjects reach adult age, considering that 
secukinumab has been approved for adults in all major markets since 2014 without any 
requirement for renal and liver safety  monitoring. Review of the trial data by [CONTACT_121907] y in pediatric subjects treated with 
secukinumab. [COMPANY_001] will continue renal and liver safet y monito ring in pediatric subjects 
(<18 years) in this study.  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
Changes to the protocol
The amendment includes changes: 
Due to C OVID -19 pandemic or an y other pandemic
Allowing shipment of study  medication to thepatient’s home (Section 5.5.2 )
Alternative options to visits ( Sections 6
, 6.5)
Local laboratory  testing for safet y purposes (Section 6.5.5 )
Home Pregnancy  testing (Section 6.5.8)
Remote PRO collection (Section [IP_ADDRESS])
Informed consent procedures (
Section 10.2)
To update safety  monitoring
Discontinuation of liver monitoring in adults (Section 7.3 )
Discontinuation of  renal monitoring in adults (Section 7.4 )
Small modifications and clarifications on Specific 
Renal Alert Criteria and Actions in 
Table 7-1 of Section 7.4.
Added Inflammatory  Bowel Disease as an example for discontinuation of study  
treatment in Section 5.5.9.
To 
manage inconsistencies in the original protocol
Added age stratum (Section 9.4.2 , 9.5.2) 

[COMPANY_001] Confidential Page 12
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
For handling of missing values/censoring/discontinuations, modified non- responder 
imputation was replaced with pure non-responder imputation. This change was in line 
with HA recommendatio n and the pi[INVESTIGATOR_121866] ( Section 9.4.3)
Added age stratum and rep laced modified non responder imputations with pure non
-
responder imputations (Section 9.4.4)
For Health
-related Quality  of Life, CDLQI 0 or 1 related text was added. The Van -
Elteren testing and Hodges- Lehmann estimates for CDLQI total score were removed 
as relevant CDLQI 0 or 1 anal ysis was already  included to compare with controls 
(Section 9.5.5)
As well as other miscellaneous minor correctio nsand clarifications.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board s
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities. This protocol 
amendment is considered substantial. The changes described inthis amended protocol require 
IRB/IEC and Health Authority  approval according to local regulations prior to implementation. 
COVID -
19 related measures may/will be implemented immediately  and prior to IRB/IEC and
HA approvals. Submission for review and approval to IRB/IEC and Health Authorities should 
occur as earl y as possibl e.
The changes herein affect the Informed Consent.  Sites are required to update and submit a
revised Informed Consent for approval that takes into account the changes described in thi s 
protocol amendment. 

[COMPANY_001] Confidential Page 13
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Summary  of previous amendments 
Amendment 3 ( April 2018)
Amendment 2 (February  2016)
Amendment 1 (April 2015)

[COMPANY_001] Confidential Page 14
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Amendment [ADDRESS_136885] been collected.  This 
analysis aligned with the efficacy  extrapolation principle, is expected to provide the basis for a 
submission package to health authorities (HA), with the inten t to allow earlier availability  of 
secukinumab to pediatric patients in countries which accept a submission of clinical data with 
use of extrapolation methodology .This analy sis may be performed before all subjects have 
reached the primary  endpoint. 
In addition to that, some clarifications, as well as editorial changes were undertaken in the 
protocol.
At the time of the protocol amendment finalization, a total of [ADDRESS_136886] thestudy  population or the study 
design.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Changes to the protocol include the following:
Section 3.5, Purpose and Timing of Interim Anal yses and Section 9.6 Interim Analy ses 
were revised with the addition
al interim analy sis information
Information for blinding relevant to the additional interim analy sis was provided in 
Section 5.4
The changes were made in data anal ysis Section 9.[ADDRESS_136887] been made in Section 9:
Clarification regarding one -sided p
-values for hy pothesis testing but two -sided for the 
others in Section 9. 
In Section 9.4.3 , clarification regarding the definition of non -responder imputation 
and emphasizing a modified approach to be used.
In Section 9.4.4 , one of the sensitivity  anal yses was changed to anal ysis using 
modified non
-responder imputation for missing data.
 
Section 5.5.10, language related to Withdrawal of Consent was updated as per European 
Economic Area’s General Data Protection Regulation (GDPR ) requirement
InSection [IP_ADDRESS] and Section 5.5.8 it is clarified that corticosteroid topi[INVESTIGATOR_121867] ,which is aligned with what is 
stated in Table 5
-2.
Clarification regarding the timing of screening visit was provided,  in form of footnote in
Table 6-1

[COMPANY_001] Confidential Page 15
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Following clarification related to drug self -administration has been added to Section 5.2, 
Section 5.5.2, Table 6-1 and Table 6 -2: 
Subjects <[ADDRESS_136888] not self -administer. However, adolescents (aged 12 to 
<18 y ears) can self -administer while under supervision by  [CONTACT_121908] l 
(HCP) or caregiver/guardian 
In Table 7 -1, clarification added regarding Protein Creatinine Ratio (PCR )analysis 
following estimated Glomerular Filtration Rate (eGFR) decrease from baseline
In Section 5.5.7 , a clarif ication wasadded regarding prior medications
Clarification that Children’s Dermatology  Life Quality  Index (CDLQI) will no longer be 
completed once the subject reaches 18 years of age was provided in , Section 6.6. 1.1and 
Table 6
-1
In  Section [ADDRESS_136889]  be reviewed b y the investigator 
Assessment schedule Table 6 -1was corrected to indicate that the optional X -ray is part of 
the screening procedure 
In Section 7.2.[ADDRESS_136890] dose should be reported to [COMPANY_001] only if the investigator suspects a causal 
relationship to study  treatment 
 
A footnote was add ed in Table 13-1 for vital signs, to indicate that values outside the 
provided ranges are considered notable 
Amendment 2 
Amendment rationale 
One key purpose for Amendment 2 is to modify  inclusion criterion 5 to align with the text 
agreed with the Pediatric Committee (PDCO) of the European Medicines Agency  (EMA).The 
inclusion criterion will now read: 
Patient being regarded by  [CONTACT_2418] a candidate for s ystemic therapy  because of: 
(1) inadequate control of sy mptoms with topi[INVESTIGATOR_35786], or 
(2) failure to respond to or tolerate previous sy stemic treatment and/or UV therapy  
As of today  only [ADDRESS_136891] 
population i s very limited. 
Another key purpose of this Amendment, is to include the Childhood Health Assessment 
Questionnaire (CHAQ©) for those subjects with History  of Psoriatic Arthritis. This addition is 
made following a request by  [CONTACT_121909] . Further to that, some protocol text 
changes were undertaken following requests from IRBs.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletion s and red underlined for insertions.

[COMPANY_001] Confidential Page 16
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
As mentioned in the rationale of Amendment [ADDRESS_136892] this revision.
Regarding addition of the CHAQ©the following protocol sections were revised or newl y 
created:
Secondary  objectives in Section 2.2 were revised. Section 6 , order of assessments and Table 6 -
1were revis ed. Section [IP_ADDRESS] was created. Section 9.5.5 was revised. Appendix 7was created 
to describe t he CHAQ©questionnaire.  
Additionally  other changes to the protocol include the following:
  
In Section 4.1 Inclusion Criteria and Synopsis text was corrected to state IGA of 4 
In Section 4.2 Exclusion Criteria, previous exclusion criteria 18 and 19 were merged into 
one. They  were previously  separate due to a t ypi[INVESTIGATOR_121868]
In Section 5.2 Treatment Arms, clarifications were provided
In Section 5.[ADDRESS_136893] dose in 
the extension treatment period occurs at Week 232 and not at EO
T
In Section 5.4 Treatment Blinding, clarifications were provided
A phrase was added in the beginning of Section 5.5 to indicate availability  of sponsor 
medical personnel to advise on trial related medical questions or problems
In Section 5.5.4 , the number of overall injections was corrected to 92 from 86 and text was 
added explaining that the removable caps of the secukinumab p re-filled sy ringes and the 
needle covers of the etanercept pre -filled sy ringes contain latex
In Section 5.5.[ADDRESS_136894]’s wish, withdrawal of consent, renal 
events and live vir us vaccinations were added to the list
In Section 5.5.12 , a clarification was provided concerning emergency  unblinding
In Table 6 -2Assessment sched ule: Added height, weight and phy sical examination at the 
8 Weeks follow up visit
In Table 6 -4PASI scoring s ystem, some t ypographical errors were corrected
A sentence was added in Section 6.5.8 to reiterate the responsibility of the sites to start 
performing urine pregnancy  testing during the study  once female subjects reach menarche 
or 12 y ears of age
In Section 7.4 Renal Safety  Monitoring, for better clarity  <49% of eGFR was replaced by  
<50%; also “abnormal serum glucose” was replaced by  “normal serum glucose”.
In Section 8.3 Data Base Management and Quality Control, clarifications were provided
Clarifications were provided and text improvements were done in
 Section 9.4 , anal ysis of 
the primary  variables and in Section 9.5, analy sis of secondary  variables. 
Section 9.4.3 Handling of missing values, was updated
Section
12References, was updated with two references for CHAQ©

[COMPANY_001] Confidential Page 17
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
  
Other minor changes like text revisions or improvements were done throughout the 
protocol, as needed
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, certain changes herein affect the Informed Consent, whi ch will be 
updated take into account the changes described in this amended protocol. 
Amendment 1
Amendment rationale
This amendment has been generated in order toprovide more details and clarification on the 
duration of contraception requested during the study  and to give option to align the duration on 
local label requirements.
The protocol has not been submitted to any Health Authorities or any Institutional Review 
Boards (IRBs)/Independent Ethics Committees (IECs). This study  has not yet started and no
patients have been enrolled. Therefore, this amendment will not influence the study population 
or results.
Changes to the protocol
Section 4.2 (Exclusion criteria 9) has been updated with regard to the duration of use of effective 
contraception and to reflect that females of child- bearing potential can only enter the study  if 
they are willing to prevent pregnancy  during the indicated duration .
Section 
6.5.[ADDRESS_136895] be informed of the need to use effective contraception during 
the indicated duration .
All changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. This amended protocol serves as the initial protocol, therefore a copy of this 
amended protocol will be sent to the Institutional Review Boards (IRBs)/Independent Ethics 
Committees (I ECs) and Health Authorities. I n addition, the changes herein affect the I nformed 
Consent, which take into account the changes described in this amended protocol.

[COMPANY_001] Confidential Page 18
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Protocol summary
Protocol number CAIN457A2310
Title A randomized, double -blind, placebo -and active controlled multicenter 
trial to demonstrate efficacy of subcutaneous secukinumab compared to 
placebo and etanercept (in a single -blinded arm) after twelve weeks of 
treatment, and to assess the safety, tolerab ility, and long -term efficacy  in 
subjects from 6 to less than 18 years of age with severe chronic plaque 
psoriasis. 
Brief title Study of efficacy and safety of secukinumab in pediatric patients with 
severe plaque psoriasis. 
Sponsor and Clinical 
Phase[COMPANY_001] 
Phase 3
Investigation type Biological
Study type Interventional
Purpose and rationale The efficacy  and safety of secukinumab has been demonstrated in 
adults in a comprehensive phase II/III program. It is now appropriate that 
a similar assessme nt is made in the pediatric population with a dosing 
regimen that can be extrapolated from the adult efficacious dose. The 
purpose of this trial is to demonstrate the efficacy  and safety of 
secukinumab compared to placebo and etanercept in children and 
adolescents aged 6 to less than 18 years with severe plaque psoriasis.
Primary Objective(s) To demonstrate the superiority of secukinumab in pediatric subjects with 
severe chronic plaque psoriasis with respect to both PASI 75 and IGA 
mod 2011 0 or 1 respons e (co -primary  endpoints) at W eek 12, 
compared to placebo.
Secondary Objectives To demonstrate superiority of secukinumab (low and high dose) in 
subjects with severe chronic plaque psoriasis with respect to PASI [ADDRESS_136896] to 
CDLQI 0 or 1 achievement at Week 12, com pared to placebo, and over 
time up to W eek 52.
To evaluate the effects of treatment of secukinumab on disability at 
Week 12 and over time up to Week 52 by [CONTACT_121910] (CHAQ©), for subjects with history of 
psoriatic arthritis
To investigate the clinical safety and tolerability of secukinumab as 
assessed by [CONTACT_121911], weight gain, tolerability of s.c. injections, vital 

[COMPANY_001] Confidential Page 19
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
signs, clinical laborator y variables, ECGs, and adverse events 
monitoring, compared to plac ebo.
Study design Multicenter, randomized, double -blind, parallel group, placebo -and 
active (etanercept) -controlled study.
12 week induction treatment period followed by a 40 week maintenance 
treatment period, a 184 week open- label extension treatment pe riod and 
a 16 week follow -up off treatment period. 
Population Pediatric subjects aged 6 years to less than 18 years with severe 
chronic plaque psoriasis. 
Approximately 160 subjects aged 6 years to <[ADDRESS_136897] 30 will be 6 years to <12 years old. 
Inclusion criteria Patient must be 6 to less than 18 years of age at the time of 
randomization (Subjects 12 to less than 18 years enrolled from 
beginning of trial; Subjects [ADDRESS_136898] 80 adolescents)
Severe plaque psoriasis, defined as a PASI score ≥ 20, and IGA 
mod 2011 score of  4, and BSA involvement of ≥10%, at 
randomization
History of plaque psoriasis for at least 3 months 
Patient being regarded by [CONTACT_2418] a candidate for 
systemic therapy because of: 
(1) inadequate control of symptoms with topi[INVESTIGATOR_35786], or 
(2) failure to respond to or tolerate previous systemic treatment 
and/or UV therapy 
Exclusion criteria Form s of psoriasis other than chronic plaque -type or drug -induced 
psoriasis, active at randomization
Female patients of childbearing potential (menarchal or become 
menarchal during the study) who do not agree to abstinence or, if 
sexually active, do not agree to the use of contraception
Active ongoing inflammatory diseases other than psoriasis that 
might confound the evaluation of the benefit of secukinumab therapy
Underlying condition (including, but not limited to metabolic, 
hematologic, renal, hepatic, pulmonary, neurologic, endocrine, 
cardiac, infectious or gastrointestinal) which in the opi[INVESTIGATOR_121869]/or 
places the subject at unacceptable risk for receiving an 
immunomodulator ytherapy
Ongoing infections as evidenced by [CONTACT_13190] X -ray, CT  scan or MRI , 
obtained within 12 weeks prior to randomization, and evaluated by a 
qualified physician
History of an ongoing, chronic or recurrent infectious disease, or 
evidence of tuberculosis i nfection
History of ly mphoproliferative disease or any known malignancy or 
history of malignanc y of any organ system within the past 5 years 
prior to screening
Investigational and 
reference therapySecukinumab tested at low dose and high dose will be available in 
prefilled syringes as a 150 mg in 1.0 mL sy ringe and a 75 mg in a 0.5 
mL syringe

[COMPANY_001] Confidential Page 20
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Secukinumab placebo will be available in prefilled syringes in a form to 
match secukinumab sy ringes
Etanercept active comparator will be provided centrally or as available in 
local markets
Efficacy assessments Psoriasis Area and Severity Index (PASI) score
PASI 50 response: subjects achieving ≥ 50% improvement 
(reduction) in PASI score compared to baseline
PASI 75 response: subjects achieving ≥ 75% improvement 
(reduction) in PASI score compared to baseline 
PASI 90 response: subjects achieving ≥ 90% improvement 
(reduction) in PASI score compared to baseline 
PASI 100 response / remission: complete clearing of psoriasis 
(PASI=0)
 
 
Investigator’s Global Assessment (IGA mod 2011; scale from 0 – 4)
Children’s Dermatology Life Quality Index
Childhood Health Assessment Questionnaire (CHAQ©)
Safety assessments Adverse Events
Physical exam
Vital signs
Height and weight
Laboratory evaluations (hematology, clinical chemistry, urinaly sis)
ECG
Pregnancy and assessments of fertility
Other assessments
Data analysis The statistical hypotheses for PASI [ADDRESS_136899] as the primary variables . 
The co-primary efficacy  variables and secondary efficacy  variable will be 
analyzed using the FAS
Key words Severe plaque psoriasis, pediatric, secukinumab

[COMPANY_001] Confidential Page 21
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
1 Introduction
1.1 Background 
Psoriasis is a chronic relapsing inflammatory skin disease with an esti mated prevalence of 0.32% 
in children under the age of 18 in 1996 (National Center for Health Statistics of the Centers for 
Disease Control and Prevention 1996). Since then, more epi[INVESTIGATOR_121870]. 
In the [LOCATION_008], prevalence of psoriasis was 0.55% in children aged 0 to 9 y ears 
and 1.37% in children and adolescents aged 10 to 19 y ears, with a higher prevalence in 
girls than in bo ys (Gelfand 2005 ). 
In German y, 0.71% of children were affected b y psoriasis and the prevalence increased 
from 0.12% at the age of 1 y ear to 1.2% at the age of 18 y ears ( Augustin 2010). 
Results from a survey  among dermatologists and general practitioners in the Netherlands 
suggested a prevalence of 0.37% in children aged 0 to 10 y
ears, and 1.09% in children 
aged 11 to 19 years ( de Jager 2009). 
In the [LOCATION_003], a Southern [LOCATION_004] study  in children enrolled in an integrated health plan 
reported a 0.30% prevalence of psoriasis in children aged 2 to 19 years. The prevalence 
increased consistently  after 5 y ears of age and was higher in females t han in males. 
Stratification by  [CONTACT_547] (males vs. females) and age group y ielded an overall prevalence 
of 0.17 % vs 0.21%; ages 2 -5 years, 0.03% vs. 0.04%; ages 6- 11 years, 0.16% vs. 0.15%; 
ages 12 -19 years, 0.25% vs. 0.33% (Wu 2011). 
The incidence of psoriasis in childhood in the US has been shown to increase with increasing 
age but also in recent years. Incidence of psoriasis in children increased significantly from 29.6 
per 100,000 in 1970- 1974 to 62.7 per 100,000 in 1995 -1999 ( Tollefson 2010).
Plaque psoriasis affects 80 to 90% of all psoriasis subjects of all age-groups (Griffiths 2007;
Pariser 2007) and hence is the most common variant in pediatric subjects. Most children 
manifest with plaque psoriasis in patterns similar to adult subjects, with lesions localized to the 
scalp, post auricular region, elbows, and knees; however, lesions in children are often smaller, 
thinner, and less scaly than those seen in adults. Involvement of the face and flexural regions is 
more common in children than adults, and psoriatic lesions in the diaper area are prevalent 
during infancy . 
As in adults, 
pediatric psoriasis is frequently  associated with significant co-morbidities like 
diabetes mellitus, Crohn’s disease, obesity , hypertension, high cholesterol, psychological and 
psychiatric impact. The overall rate of comorbid conditions in psoriasis subjects under [ADDRESS_136900] psoriasis ( Augustin 2010 ). A pediatric study 
using an international cohort of psoriasis subjects found that a significantly  higher percentage 
of children with psoriasis showed excess adiposi ty (37.9% vs. 20.5%) or obesity  (20.2% vs 
7.3%), significantl
y higher than the general pediatric population ( Paller 2013).
The psychological impact of psoriasis can be particularl y traumatic to children and adoles cents. 
In children with at least one of [ADDRESS_136901] 
significant problem 
affecting their health- related quality of life (Beattie 2006). Psoriasis, a 

[COMPANY_001] Confidential Page 22
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
debilitating and disfiguring skin condition, is an independent risk factor for psychiatric 
comorbidities in children and adolescents. Compared with a matched psoriasis- free control 
cohort in a study  based on health services claims data in the [LOCATION_003], pediatric subjects had 
approximately  25% to 30% greater risks of being given a diagnosis of an y psychiatric disorder, 
depression, or anxiety  subsequent to the psoriasis diagnosis ( Kimball 2012).
Due to the higher prevalence of plaque psoriasis in children compared to other types and the 
significant physical and psychological burden it carries in the pediatric population, [COMPANY_001] 
plans to study secukinumab in the treatment of plaque psoriasis in patients from [ADDRESS_136902] line of treatment for 
skin-limited disease. With chronicity  of illness and in more severe cases, phototherapy  and 
systemic therapy  are added to help induce remission ( Silverberg 2009 ). 
Topi[INVESTIGATOR_121871] y of prescriptions (57 to 91%), while systemic agents 
are rarely used (4%), and biologics being even more rarely  used (0.4%) (Wu 2011, Kimball 
2012). Commonly  used topi[INVESTIGATOR_121872], coal tar, 
anthralin, calcipotriol either alone or in combination with topi[INVESTIGATOR_8826], tazarotene and 
calcineurin inhibitors ( Burden 1999 , Farber 1999 , Benoit 2007
). None of these treatments have 
been approved for the treatment of psoriasis in children below [ADDRESS_136903] -line phototherapy  because it is similarly effective as 
Psoralen + UVA (PUVA), more convenient, and less carcinogenic (Van Weelden 1990). PUVA 
therap y is not generall y recommended in children, but may  be used with caution in adolescents 
(Burden 1999
).
Systemic therap y is usually considered if the disease is moderate to severe in intensity, and not 
adequatel y controlled by [CONTACT_12523][INVESTIGATOR_12491]. Systemic treatments approved for use in adult 
psoriasis include acitretin, methotrexate, cyclosporine, and biologics. Acitretin is approved for 
subsets of psoria tic pediatric patients in some EU countries and Switzerland. However 
cyclosporine and methotrexate are not currentl y approved for the treatment of 
children/adolescents suffering from psoriasis. While there is no biologic approved for the 
treatment of psoriasis in subjects below the age of [ADDRESS_136904] s with 
psoriasis ( de Jager 2010 , Luu  2013 ). In Europe, Enbrel (etanercept) was approved in 2011 for 
“Treatment of chronic severe plaque psoriasis in children and adolescen ts from the age of 6 
years who are inadequately controlled by, or are intolerant to, other systemic therapi[INVESTIGATOR_121873]”. Approval was based on a double -blind, placebo controlled study  in moderate 
to severe pediatric subjects (Paller 2008 ); a retrospective analysis of results in severe subjects 
aged from 8 to 17 years showed that PASI  75 at Week 12 was achieved in 54.7% of subjects 
receiving etanercept vs. 11.3% of subjects receiving placebo, p<0.001 ( Landells 2010 ).
Use of methotrexate, cyclosporine, retinoids (particularl y acitretin), and, with a much lower 
frequency , dapsone and hydroxyurea has been reported in the literature (Zappel 2004 ;Benoit 
2007). Most experience has been reported with retinoids, but the potential effect on bone growth 

[COMPANY_001] Confidential Page 23
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
and teratogenicit y limit their use in children and adolescents. Use of cyclosporine and 
methotrexate is limited by [CONTACT_121912] (AE) profile (kidney  dysfunction, hypertension 
and liver dysfunction, respectively ). Reports on the use of biologics in pediatric patients are 
scarce ( Benoit 2007 ).
In summ ary, a very limited number of systemic drugs for the treatment of psoriasis are approved 
for children, and the few approved drugs all have severe limitations. There is a high medical 
need to evaluate the treatment of psoriasis in patients less than 18 year s of age where controlled 
studies are mostly  missing (Burden 1999; Farber 1999 ; Benoit 2007 ; Paller 2008). 
Secukinumab (AIN457) is a recombinant high-affinity  fully human monoclonal anti-human 
Interleukin -17A (IL-17A) antibody  of the IgG1/κ -class. Secukinumab binds to human IL-17A 
and neutralizes the bioact ivity of this cytokine. IL-17A is the central lymphokine of a newl y 
defined subset of inflammatory  T cells, the Th17 cells which, in several animal models, are 
pi[INVESTIGATOR_121874]. IL-17A is mainly  produced by 
[CONTACT_121913]4+ and CD8+ T lymphocy tes. IL-17A is being recognized as one of the 
principal pro-inflammatory  cytokines in immune mediated inflammatory  diseases. Its 
neutralization is expected to treat the underl ying pathophy siology  of immune mediated disease, 
and as a consequence provide relief of s ymptoms.
In adult phase II/III studies, secukinumab [ADDRESS_136905] bo over 12 weeks and etanercept over 52 weeks of treatment (Langley 
2014).
Based on the natural history of psoriasis and the similar clinical features and histology in adults 
and pediatric population ( Burden 1999
; Farber 1999; Benoit 2007), it is expected that a human 
monoclonal antibody  such as secukinumab will have an identical mode of action in children 
and would be metabolized similarly  when compared to adults. Now that efficacy  and safet y 
have 
been demonstrated in adults in a comprehensive phase II/III program, it seems appropriate 
that the pediatric population can be exposed to secukinum ab in long term studies with a dosin g 
regimen that is extrapolated from the adult efficacious dose.
1.2 Purpose 
The purpose of this stud y is to demonstrate superior efficacy of secukinumab versus placebo at 
Week 12, based on both PASI  75 and IGA mod 2011 0 or 1 response rates in children and 
adolescents aged 6 to less than 18 years with severe chronic plaque psoriasis who are candidates 
for systemic therapy  because of: (1) inadequate control of sy mptoms with topi[INVESTIGATOR_35786], or 
(2) failure to respond to or t olerate previous sy stemic treatment and/or UV therapy . Moreover, 
this study  will assess the long term safety  and tolerability  of secukinumab in this pediatric age 
group  
 

[COMPANY_001] Confidential Page 24
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
2 Study  objectives
2.1 Primary  objective(s)
To demonstrate the superiorit y of secukinumab (low and high dose) in pediatric subjects with 
severe chronic plaque psoriasis with respect to both PASI 75 and IGA mod 2011 0 or 1 response 
(co-primary  endpoints) at Week 12, compared to placebo.
2.2 Secondary  objectives
To demonstrate superi ority  of secukinumab (low and high dose) in subjects with severe 
chronic plaque psoriasis with respect to PASI 90 response at Week 12, compared to 
placebo.
To assess efficacy  of secukinumab in subjects with severe chronic plaques psoriasis with 
respect to PASI 50 and PASI  100 at Week 12, compared to placebo.
To assess efficacy  of secukinumab in subjects with severe chronic plaque psoriasis with 
respect to PASI 50, PASI 75, PASI  90 , PASI 100 and IGA mod 2011 0 or 1 at Week 16 
and over time up to Week 52.
Toassess the efficacy  of secukinumab with respect to changes in PASI  score and IGA 
mod 2011 score at Week 12, compared to placebo, and over time up to Week 52.
To investigate the effects of treatment with secukinumab with respect to changes in 
CDL QI at Week 12, compared to placebo, and over time up to Week 52.
To investigate the effects of treatment of secukinumab with respect to CDLQI 0 or 1 
achievement at Week 12, compared to placebo, and over time up to Week 52.
To evaluate the effects of treatment of sec ukinumab on disability  at Week 12 and over 
time up to Week 52 by  [CONTACT_121914] (CHAQ©), 
for subjects with history  of psoriatic arthritis.
To investigate the clinical safet y and tolerability of secukinumab as assessed by [CONTACT_121911], 
weight gain, tolerability of s.c. injections, vital signs, clinical laboratory  variables, ECGs, 
and adverse events monitoring, compared to placebo.

[COMPANY_001] Confidential Page 25
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
3 Investigational plan
3.1 Stud y design
This is a multicenter, randomized, double -blind, placebo- and active -controlled (etanercept in 
single blinded arm) study  in pediatric subjects aged 6 years to less than 18 years with severe 
chronic plaque psoriasis. Approximately  160 subjects aged 6 years to <[ADDRESS_136906] 30 will be 6 years to <12 years old. It is expected that subjects will be enrolled 
at approximately  70 study  sites worldwide.
Two age subgroups will be studied in a staggered approach within this clinical stud y: 12 to l ess 
than 18 years of age, and 6 to less than 12 years of age (age for the subgroups determined at the 
time of randomization). Enrolment of children aged 6 to less than 12 years will begin after a 
favorable recommendation by [CONTACT_121915] (DMC) 
who will review data of approximately  80 (approximately  40 treated with secukinumab) 
enrolled adolescents (aged 12 to less than 18 years) treated for [ADDRESS_136907] ed and 
analyzed.
Subjects will be randomized using a 1:1:1:1 ratio into one of the treatment arms: secukinumab 
low dose, secukinumab high dose, etanercept or placebo. Subjects randomized to secukinumab 
treatment arms (high dose and low dose) will receive dose based on the weight category  (<25 
kg, 25 to <50kg, ≥50 kg). If a subject moves into a higher or lower weight group at two 
consecutive visits with weight measurements during the maintenance (from Week 12 onwards 
as assessed at monthl y visits, i.e. Week 13, 14, 15 will not be taken into account) or during 
extension treatment period (as assessed at scheduled site visits), the subject will receive dosing 
according to the new (higher or lower) weight group respectivel y. 

[COMPANY_001] Confidential Page 26
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Figure 3-1 Study  design
The study  consists of 5 Epochs: screening (up to 4 weeks), induction (of 12 weeks), 
maintenance (of 40 weeks), extension treatment epoch (open -label of 184 weeks) and post-
treatment follow -up epoch (of 16 weeks). An outline of the visits is presented in Figure 3
-1, 
while a detailed visit and assessment schedule can be found in Table 6-1 , Table 6 -2.
Screening Epoch
The screening epoch of up to 4 weeks will be used to assess eligibility  of the subjects and to 
taper subjects off prohibited medications.
Induction Epoch
The induction epoch is defined as randomization through Week 12 (prior to dose). In this epoch 
the study  is both active and placebo -controlled and at its completion the primary  endpoint is 
assessed (Week 12). 
At the start of the induction epoch, eligible subjects will be randomized in a 1:1:1:1 ratio into 
one of four treatment groups (etan ercept, secukinumab low dose group, secukinumab high dose 
group, or placebo group). The randomization will be stratified by  [CONTACT_654] (<12 y ears or ≥12 y ears) 
and weight (<25, 25-<50, ≥50) at randomization; Subjects randomized to the secukinumab 
treatment group will receive respective high and low doses according to their weight category . 
Subjects randomized to the placebo group will be pre-assigned to either the low-or high-dose 
group of secukinumab, at the Randomization visit, in case they are not achieving a PASI  75 
response as assessed at Week 12.  During the induction epoch, all subjects will be visiting the 
study  site at Randomization and Weeks 1, 2, 3, 4, 8, and 12. The secukinumab and placebo 
treatment groups will receive s.c. study  treatment and/or s.c. placebo weekly  for four weeks 
(randomization and Weeks 1, 2, and 3) and then one dose of study  treatment and/or placebo at 

[COMPANY_001] Confidential Page 27
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Weeks 4 and 8 (last dose during the induction epoch). Secukinumab will be administered at site. 
Subjects in the etanercept arm will r eceive weekly s.c. dose of 0.8 mg/kg (up to a maximum of 
50mg) of open -label etanercept. Etanercept will be administered at site during site visits and at 
home or at the site for the remaining weekly  visits based on the visit schedule (Table 6-1and 
Table 6
-2).
Assessments for the primary  endpoint will be done at Week 12 for all treatment arms prior to 
the dose at Week 12.
For subjects who discontinu e study  treatment for any reason before the end of the induction 
epoch, an EOI Visit (Week 12 Visit) should be performed approximately  four weeks after their 
last dose of study  drug and then the subject will enter the post -treatment follow -up period and 
perform F4, F8, F12 and F16 visits. If subjects start another systemic anti psoriatic treatment 
during follow up, they  do not need to continue with the remaining follow -up visits but they will 
be expected to return to site after the start of the systemic treatment and perform End of Follow -
up (EOF) visit.
Placebo PASI [ADDRESS_136908] visit F4 and four weeks later perform visit EOF and complete the study . If subjects 
start another systemic anti psoriatic treatment during follow up, they do not need to perform the 
remaining follow -up visits but they will be expected to return to site after the start of the 
systemic treatment and perform End of Follow- up (EOF) visit.
Maintenance Epoch 
The maintenance epoch is defined as Weeks 12 (from dosing) through Week 52. In this epoch 
the study  is active -controlled and the objectives focus on the maintenance of the respons e 
observed at Week 12.   
Subjects who were receiving secukinumab or etanercept during induction will continue in 
maintenance with the same treatment. 
Subjects who 
were on placebo during induction and at Week [ADDRESS_136909] dose of the 
maintenance epoch and is followed by  [CONTACT_121916] t and / or placebo 
weekl y up to Week 15, and every four weeks starting at Week 16 and up to Week 48.
Assessments for all the treatment arms will be done at Week 52 prior to dose at Week 52.
The Week 52 visit is the planned End of Maintenance epoch (EOM) visit. The EOM visit is 
considered complete when week 52 assessments are finished.

[COMPANY_001] Confidential Page 28
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
At the end of the maintenance epoch, subjects on secukinumab will enter the open -label 
extension treatment epoch of the study  whereas subjects on etanercept will enter the post-
treatment follow -up epoch and thereafter will complete the study .
For subjects who discontinue study treatment for any reason before the end of the maintenance 
epoch, the Week 52 Visit (planned End of Maintenance Period (EOM) visit) should be 
performed approximately [ADDRESS_136910] -treatment follow -up epoch and perform F4, F8, F12 and 
F16 (EOF) visits. If subjects start another systemic anti psoriatic treatment during follow up, 
they do not need to continue with the remaining follow -
up visits but they will be expected to 
return to site after the start of the systemic treatment and perform End of Follow -up (EOF) visit.
Extension Treatment Epoch
The extension treatm ent epoch is defined as Week 52 (from dosing) until Week 236. At this 
epoch the subjects are all treated with secukinumab and the purpose is the collection of long 
term safet y and efficacy data.  
At the end of the maintenance epoch, all subjects on secuki numab will enter the extension 
treatment epoch of the study  and will continue to receive the same dose of secukinumab they 
had received at completion of maintenance epoch. 
Subjects who participated in the maintenance epoch but prematurel y discontinued thestudy  will 
not be able to enter the extension treatment epoch of the study . Patients receiving etanercept 
will not be eligible to enter the extension treatment epoch. Instead, at Week 52, they will 
complete an EOM visit and then enter the post-treatment follow -up epoch. The first 
secukinumab dose of the Extension Treatment epoch is administered at Week 52. Subsequent 
doses of secukinumab will be administered every  four weeks until the End of Treatment (EOT). 
For subjects who discontinue study  treatment forany reason before the end of the extension 
treatment epoch, the End of Extension Treatment (EOT) visit should be performed 
approximately  [ADDRESS_136911]-treatment follow -up epoch (perform F4, F8, F12 and F16 visits). If subjects start another 
systemic anti psoriatic treatment during follow up, they do not need to continue with the 
remaining follow -up visits but they will be expected to return to site after the start of the 
systemic treatment and perform End of Follow -up (EOF) visit.
Follow -up Epoch 
The treatment -free follow -up visits will be at Week 240 (Post -treatment Follow -up visit F4, 
which is [ADDRESS_136912] dose of secukinumab), Week 244 (Post -
treatment Follow -up visit F8, which is [ADDRESS_136913] dose of 
secukinumab), Week 248 (Post -treatment follow -up visit F12) and Week 252 (Post -treatment 
follow -up visit F16 (i.e. EOF, End of follow -up)). Subjects who complete or discontinue t he 
treatment are expected to perform the complete treatment- free follow up period unless they start 
another systemic anti psoriatic treatment. In this case they do not need to continue with the 
remaining follow up visits but they will be expected to return to site after the start of the 
systemic treatment and perform End of Follow- up (EOF) visit.    

[COMPANY_001] Confidential Page 29
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Subjects who completed the extension treatment epoch will enter the treatment -free follow up 
epoch. In addition, the following subjects will enter the treatmen t-free follow up epoch:
Subjects randomized to placebo that were PASI 75 responders at the End of Induction 
(EOI) epoch and completed the End of Induction (EOI) visit. These subjects are not 
eligible to continue to maintenance. These subjects are expected to do F4 (Post -treatment
Follow -up visit F4, which is [ADDRESS_136914] study  treatment) and 
four weeks later perform the End of Follow -up (EOF) visit and complete the study . 
Subjects who discontinued prematurel y from the induction epoch. (Subjects should be
scheduled for the EOI visit approximately  [ADDRESS_136915] treatment dose and then 
enter the treatment- free follow up epoch.)  
Subjects on secukinumab who completed the maintenance epoch and the EOM visit and 
do not want to continue into the exte nsion treatment l epoch. 
Subjects on etanercept arm who completed the maintenance epoch and the EOM visit.  
These subjects are not eligible to continue into extension treatment epoch.
Subjects who discontinued prematurel y from the maintenance epoch. (Subj ects should be 
scheduled for the EOM visit approximately  [ADDRESS_136916] treatment dose and 
then enter the treatment- free follow up epoch).  
Subjects who discontinued prematurel y from the extension treatment epoch. (Subjects 
should be scheduled f or the EOT visit approximately  [ADDRESS_136917] treatment 
dose and then enter the treatment -free follow up epoch). 
3.[ADDRESS_136918] unmet medical need. The lower age of enrollment has been 
limited to 6 y ears since the prevalence of psoriasis in the 0 to less than 6 age group is very  low 
(with the highest prevalence published of 0.3%) and the proportion of children with a severe 
condition in need of a systemic treatment is 4%, giving a final prevalence of the condition to be 
about 1 per 10,000 in this age group. 
3.3 Rationale of dose/regimen, route of administration and duration 
of treatment
The dose selection for secukinumab in pediatric psoriasis subjects is based on the recentl y 
completed phase III program in adults as well as modeling and simulation based on the results 
from adult phase II/III studies. Secukinumab 300 mg and 150 mg are selected based on evidence 

[COMPANY_001] Confidential Page 30
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
from adult phase III studies that demonstrated both doses to be safe and effective in treating 
moderate to severe plaque psoriasis. 
The proposed doses for the high dose and low dose secukinumab arms are based on a 
population -PK model that has been built based onthe pool of key phase II/III trials to predict 
exposure of secukinumab according to various body  weights (Figure 3-2). This dosing rationale 
assumes that the concentration -response relationship and disease characteristics (onset, severit y, 
progression) in children are similar to adults with no major differences in target expression of 
IL-17A. Therefore, similar PK concentration profiles across the adult and pediatric populations 
will achieve comparable response.
Figure 3 -2 Average concentration for the proposed low dose and high dose 
secukinumab arms     
                 
Extrapolation of the exposure in children / ado lescents in a bod ywei ght range down to 20 kg to 
allow maintaining exposure levels similar to those observed in adults with 50 
kg body  weight 
led to selection of 75mg, 150 mg and 300 mg within weight categories as follows:
Subjects ≥50 kg: 150 mg (low dose group) or 300 mg (high dose group)
Subjects 25 kg to < 50 kg: 75 mg (low dose group) or 150 mg (high dose group)
Subjects < 25 kg: 75 mg (for both dose groups in order to ensure no overl y high exposures in 
this sub- population).
The dosing regimen used is consistent with that of adults and the total stud y duration including 
one year of blinded treatment plus the open -label extension treatment epoch and follow -up 
epoch (>5 drug half -lives) will allow for assessment of long term safet y and efficacy.
3.4 Rationale for choice of comparator
The use of placebo is in accordance with health authority  guidelines (FDA Guidance E10, and 
EMEA/CPMP Position Statement (EMEA/[ZIP_CODE]/01) and the Declaration of Helsinki I tem 32.  
Etanercept was chosen as an active comparator, since it is the first biologic medication approved 
for use in children and adolescents with severe psoriasis in the European Union and elsewhere 
High dose

[COMPANY_001] Confidential Page 31
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
and is in accordance with Health Authority  feedback. However there will be no formal 
comparison between secukinumab and etanercept treatment groups.  
The placebo arm is double blinded and the etanercept arm is single (efficacy  assessor) blinded 
to prevent observer bias, and not subject -blinded because the dosing regimens of the two 
products are so different that double blinding is considered inappropriate in children due to the 
number of additional placebo injections needed in order to achieve a true double -blind 
administration. Site personnel performing the efficacy  assessments, will be blinded to all 
treatment allocat ion, whilst site personnel performing the remaining assessments will be 
blinded to the secukinumab/secukinumab placebo allocation only  (see also Section 5.4).
3.5 Purpose and timing of interim analy ses/design adaptations
An interim analysis for the sole purpose of evaluating safet y and efficacy in the adolescent 
population will be conducted once at least 80 adolescents complete 28 weeks of treatment 
(dosed up to Week 24). Enrollment of the pediatric population aged 6 to less than 12 years will 
begin only if there are no serious efficacy  and/or safet y concerns based on DMC’s 
recommendation. No conclusions regarding demonstration of efficacy  affecting the conduct of 
the study  will be made.
A full analy sis, includi
ng the primary  endpoint (at week 12) analysis will be conducted when 
all subjects have completed the Week [ADDRESS_136919] been collected, this analysis, 
aligned with efficacy  extrapolation principle, is expected to provide the basis for a submission 
package to health autho rities (HA). The intention of this interim anal ysis is to potentially make 
secukinumab available to pediatric patients sooner, by  [CONTACT_121917], in countries which accept a submission of clinical data with use of extrapolation 
methodology . This analysis may be performed before all subjects have reached the primar y 
endpoint . It is expected that data from at least approximately  100 patient years of secukinumab 
treatment will be included in this analy sis
.
Efficacy  and saf ety data collected during the extension treatment epoch (until the end of study) 
may bereported yearly in separate reports.
If requested by [CONTACT_6628], additional interim analyses may be performed for instance 
on  data to confirm modeling assumptions. For these occasions  
will share data with  in a blinded fashion. Overall, should such requests 
occur during the blinded portion of the study , they will be performed without unblinding of 
[COMPANY_001] pe rsonnel. Unblinded data will onl y be made available to independent [COMPANY_001]/CRO 
individuals involved in the preparation of the interim analy ses and who are not directly  involved 
in the study  conduct.
3.6 Risks and benefits
Biologics like secukinumab are an attractive option for treating psoriasis in the pediatric 
population as they are convenient to use, requiring less frequent dosing than traditional systemic 

[COMPANY_001] Confidential Page 32
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
agents such as methotrexate, cyclosporine, and acitretin. In addition, they lack many of the 
potential end-organ toxicities of traditional agents because of their targeted action. 
Non-clinical studies and phase II and III clinical studies in adults have not shown any 
impediment to using secukinumab subcutaneously  in man. In adult studies, secukinumab has 
shown a very good efficacy  profile in the treatment of moderate to severe chronic plaque 
psoriasis. The safety data from the completed and ongoing studies including AE and SAE data, 
laboratory  parameters and immunogenicity  data demonstrate a good safety  profile which 
included an observed risk of infections in particular candida infections and neutropenia or 
hypersensitivity  reactions that can be seen with administration of foreign proteins. Most of the 
infections were non -serious, mild to moderate in severi ty, clinicall y easily manageable and did 
not lead to treatment discontinuation. Cases of neutropenia were uncommon, generally  mild to 
moderate and transient and did not lead to treatment discontinuation, and only a few cases were 
timely  associated with non- serious infections.
Potential risks for subjects on secukinumab include malignancies, major adverse cardiovascular 
events (MACE), Crohn’s disease, immunogenicity, and interactions with live vaccines.
Since the immune system was shown to reach adult levels of maturation by 6 years of age 
(Comans- Bitter 1997), no adverse effects of secukinumab on development of this system are 
expected in this trial’s pediatric population (age 6 to <18y ears). Consequently , no additional 
risks of infections, malignancies, or impact on peripheral competent immune cells over those 
described for adults are anticipated for this pediatric group.
A potential for increased exposure of secukinumab at lower body  weights has been suggeste d 
by [CONTACT_121918]. Consequentl y, weight category  based 
dosing has been instituted to ensure that exposure levels of secukinumab are comparable across 
all weight groups in the study  population.
No adverse effects are antic ipated with respect to linear bone growth and development given 
the absence of bone findings in knock -out mice ( Kokubu 2008) and in toxicology  studies with 
secukinumab. Height to measure linear growth will be monitored all through the study . 
Potential risks for subjects on etanercept could include common side effects of etanercept 
namely  injection site reactions, upper respi[INVESTIGATOR_121875], and headache. Injection site 
reactions such as redness, rash, swelling, itching, or bruising usually  subside within 3 to 5 days. 
The subjects may  also be at increased risk for infections and possibly cancer, as etanercept is a 
medication that has the potential to suppress the immune sy stem.
Prior to participating in a clinical trial with secukinumab, participants should consider 
completion of all age appropriate immunizations according to immunization guidelines. 
Subjects treated with secukinumab should not receive live vaccines. Non-live vaccinations 
received during secukinumab treatment may not elicit an immune response sufficient to prevent 
disease.

[COMPANY_001] Confidential Page 33
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
[ADDRESS_136920] of male and female subjects age 6 to less than 18 years of age 
(at the start of study  treatment) with severe plaque psoriasis who are candidates for systemic 
treatment.
The investigator must ensure that all subjects being considered for the study  meet the following 
eligibility  criteria. No additional exclusions should be applied by [CONTACT_093], in order that 
the study  population will be representative of all eligible subjects.
4.[ADDRESS_136921] to fulfill all of the following criteria:
1. Written informed assent and parental permission (age as per local law) obtained at 
screening before any assessment is performed. Of note, that if subjects reach age of 
consent (age as per local law) during the stud y, they will need to also sign the 
corresponding stud y Informed Consent(s). 
2.Must be [ADDRESS_136922] 80 adolescents 
3.Severe plaque psoriasis, defined as a PASI  score ≥ 20, and IGA mod 2011 score of 4, and 
BSA involvement of ≥10%, at randomization
4.History  of plaque psoriasis for at least 3 months 
5.Patient being regarded by  [CONTACT_2418] a candidate for s ystemic therapy  because 
of: 
(1) inadequate control of sy mpto ms with topi[INVESTIGATOR_35786], or 
(2) failure to respond to or tolerate previous sy stemic treatment and/or UV therapy  
4.2 Exclusion criteria
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study . No 
additional exclusions may be applied by [CONTACT_093], in order to ensure that the study 
population will be representative of all eligible subjects.
1.Forms of psoriasis other than chronic plaque -type (e.g., pustular, ery throdermic and 
guttate psoriasis), active at randomization
2.Drug -induced psoriasis (i.e., new onset or current exacerbation from beta -blockers, 
calcium channel blockers or lithium)
3.Ongoing use of prohibited treatments as mentioned in Table 5-2 (Washout periods as 
detailed in Table 5-[ADDRESS_136923] to be adhered to). 
4.Previous exposure to secukinumab or any  other biologic drug directl y targeting IL -17 or 
the IL -17 receptor, or to etanercept 
5.Use of an y other investi gational treatment within 4 weeks before randomization, or within 
a period of 5 half -lives of the investigational treatment, whichever is longer.

[COMPANY_001] Confidential Page 34
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.History  of severe hy persensitivity  reaction or anaphy laxis to any  biological agents (human 
monoclonal antibody or soluble receptor)
7.Pregnant or nursing (lactating) females, where pregnancy  is defined as the state of a 
female after conception and until the termination of gestation, confirmed b y a positive 
hCG laboratory  test
8.Female patients (< 18 years of age) of c hildbearing potential (menarchal or becoming 
menarchal during the study ) who do not agree to abstinence or, if sexually  active, do not 
agree to the use of contraception as defined in Section 6.5.8   
9.Female patients (who become ≥18 y ears of age during the study ) of child- bearing 
potential, defined as all women physiologicall y capable of becoming pregnant, unless they 
are using effective methods of contraception during dosing of study  treatment and for a 
minimum of 16 weeks after stoppi[INVESTIGATOR_105762] y treatment or longer if local label requires it 
(e.g. in EU 20 weeks). Effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic ab stinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment.  I n 
case of oophorectom y alone, only  when the reproductive status of the woman has 
been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject
Barrier methods of contraception: 
a.Male or female condom with or without spermicide 
b.Cap, diaphragm or sponge with spermicide 
Use of oral, injected or implanted hormon al methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception
Placement of an intrauterine device (IUD) or intrauterine s ystem (I US)
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of 3 months before taking stud y treatment
10.Active ongoing inflammatory  diseases other than psoriasis that might confound the 
evaluation of the benefit of secukinumab and/or etanercept therapy
11.Underl ying condition (including, but not limited to metabolic, hematologic, renal, hepatic, 
pulmonary , neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the 
opi[INVESTIGATOR_121876]/or places the 
subject at unacceptable risk for receiving an immunomodulatory  therapy
12.
Investigator discretion should be used for subjects with preexisting or recent -onset central 
or peripheral nervous s ystem demy elinatin g disorders
13.Subjects with a Glomerular Filtration Rate (eGFR), estimated by  [CONTACT_12800], 
of  < 60 mL /min/1.73 m2at screening. Assessment may  be repeated once, two or more 

[COMPANY_001] Confidential Page 35
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
days later, and if eGFR value 60, subject may  be included at the discret ion of the 
investigator.  
14.Subjects with total WBC count <2,500/μL , or platelets <100,000/μL  or neutrophils 
<1,500/μL  or hemoglobin <8.5 g/dL at screening
15. Ongoing infections and in particular tuberculosis. If warranted for a subject and based on 
the investigator’s judgment, an X -ray or MRI (at pre specified sites) may  be performed as 
part of the screening procedure.  
16.Active sy stemic infections during the last two weeks (exception: common cold) prior to 
randomization and any infections that reoccur on a regular basis.
17.Investigator/qualified site staff discretion should be used regarding subjects who have 
traveled or resided in areas of endemic m ycoses, such a s histoplasmosis, 
coccidioidomy cosis or blastomy cosis and for subjects with underl ying conditions that may  
predispose them to infection, such as advanced or poorly  controlled diabetes
18.History  of an ongoing, chronic or recurrent infectious disease, or evide nce of tuberculosis 
infection as defined b y a positive QuantiFERON TB -Gold test (QFT) at screening.
Subjects with a positive QFT test may  participate in the study  if further work up 
(according to local practice/guidelines) establishes conclusively that the subject has no 
evidence of active tuberculosis. I f presence of latent tuberculosis is established, then 
treatment must have been initiated and maintained according to local country  guidelines 
prior to randomization. 
19.Known infection with HIV, hepatitis B or hepatitis C at screening 
20.History  of lymphoproliferative disease or an y known malignancy  or history  of malignancy  
of an y organ s ystem within the past 5 y ears prior to screening
21.Plans for administration of live vaccines during the study  period or within 6 weeks prior to 
randomization.
22.Any medical or ps ychiatric condition which, in the I nvestigator’s opi[INVESTIGATOR_1649], would preclude 
the participant from adhering to the protocol or completing the study  per protocol.
23.Hypersensitivity  or allergy  to any  of the ingredie nts of study  treatments, including 
etanercept.
24.History  or evidence of ongoing alcohol or drug abuse, within the last 24 weeks before 
randomization.
25. Subjects not willing to limit UV light exposure (e.g., sunbathing and/or the use of tanning 
devices) during the course of the study .
26. Unwillingness to undergo repeated venipuncture or subcutaneous injections.
5 Treatment
5.1 Protocol requested treatment
5.1.1 Investigational treatment
The following stud y treatments will be used:
Investigational drug

[COMPANY_001] Confidential Page 36
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Secukinumab prefilled s yringes, available as a 150 mg in 1.0 mL  and as a 75 mg in 0.5 
mL syringes. Provided by [CONTACT_5343].
Reference therapi[INVESTIGATOR_014]
Secukinumab placebo: secukinumab placebo available as 1 mL and 0.5 mL prefilled 
syringes, provided by  [CONTACT_15024] a form to match secukinuma b prefilled syringes.
Etanercept active comparator (not a biosimilar): 
a.as provided centrall y by a CRO or
b.as available and purchased locally  
All study  treatments will be labelled appropriatel y.
5.1.2 Additional study treatment
No additional treatment bey ond investigational treatment is requested for this trial.
5.2 Treatment arms 
Subjects will be randomized using a 1:1:1:1 ratio into one of the treatment arms mentioned 
below. Subjects randomized to secukinumab treatment arms (high dose and low dose) will 
receive dose according to the weight category  (<25 kg, 
25- <50kg, ≥50 kg). 
Subjects in the two secukinumab arms weighing ≥50kg will receive 150 mg (low dose group) 
and 300 mg (high dose group), 25 to <50 kg will receive 75mg (low dose group) and 150 mg 
(high dose group) and <25kg will receive 75mg for both dose groups. In order to maintain the 
treatment blind, all subjects in secukinumab or placebo arms will receive 2 s.c. injections at 
each dose, except for subjects <25kg weight category  who will receive only 1 injection of either 
75 mg secukinumab or matching placebo (Table 5 -1).

[COMPANY_001] Confidential Page 37
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Table 5-1 Secukinumab/Placebo treatment arms and injections at each visit 
during Induction and maintenance epoch 
Weightcategory at 
randomizationTreatment arms Blinded Dose (PFS) Number of 
injections at each 
visit during 
Induction Epoch Number of 
injections at each 
visit during 
Maintenance 
Epoch
<25 kg AIN high dose 75mg/0.5mL  AIN 1 1
AIN low dose 75mg/ 0.5mL AIN 1 1
Placebo high 
dose(pre 
assigned at 
randomization)75mg/0.5mL AIN PBO 
1 1*
Placebo low dose 
(pre-assigned at 
randomization)75mg/0.5mL AIN PBO 
1 1*
25 to <50kg AIN high dose 2x75mg/0.5mL AIN 2 2
AIN low dose 75mg/0.5mL AIN 
+75mg/0.5mL AIN PBO2 2
Placebo high 
dose(pre 
assigned at 
randomization)2x75mg/0.5mL AIN 
PBO2 2*
Placebo low dose 
(pre-assigned at 
randomization)2x75mg/0.5mL AIN 
PBO 2 2*
≥50kg AIN high dose 2x150mg/1.0ml  AIN 2 2
AIN low dose 150mg/1.0mL 
AIN+150mg/1.0mL AIN 
PBO2 2
Placebo high 
dose(pre 
assigned at 
randomization)2x150mg/1.0mL AIN 
PBO 2 2*
Placebo low dose 
(pre-assigned at 
randomization)2x150mg/1.0 mL AIN 
PBO 2 2*
*Placebo PASI 75 non responders will start receiving at W eek 12 active treatment (secukinumab) high or low, as 
preassigned at randomization
Etanercept active comparator group : S.C. etanercept 0.8mg/kg (up to a maximum 
dose of 50 mg) once per week, for 51 weeks administered at home (self -injected or by 
[CONTACT_84452]) or at the study site. No subject blinding will be introduced for this arm, but 
the efficacy  assessor will be blinde d as regards to treatment assignment. 
Secukinumab low dose group : According to the weight category , s.c. secukinumab 
75mg (in <25 kg and 25 to <50kg) or 150 mg (≥50kg) injections at Randomization, 
Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab 
at Weeks 13, 
14 and 15 during the blinded phase of the study ; thereafter at Week 52 
and every  4 weeks during the extension treatment epoch until Week 232. Subjects and 
all site staff will be blinded as regards to treatment assignment and secukinumab dose 
levels during the induction and maintenance epochs. After data base lock for Week 52 

[COMPANY_001] Confidential Page 38
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
analysis has been performed, the placebo injection will no longer be administered and 
the study  will become open label. In the extension treatment epoch, between the site 
visits, subjects will be expected to perform the study  treatment administrations at home. 
This can be self-administered by [CONTACT_121919]. Subjects <[ADDRESS_136924] not self-administer. However, adolescents (aged 12 to <18 years) can self-
administer while under supervision of HCPs or caregiver/guardian. If subject/parent do 
not feel confident in performing treatment administration at home they are still allowed 
to receive stud y treatment administration at site.
Secukinumab high dose group : According to the weight category  , s.c. secukinumab 
75mg (in <25 kg), 150mg (25 to <50kg), 300 mg (≥50kg) injections at Randomization, 
Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab 
at Weeks 13, 14 and 15 during the blinded phase of the study ; thereafter at Week [ADDRESS_136925] or by [CONTACT_84452]. Subjects <[ADDRESS_136926] not self-administer. However, adolescents (aged 12 to <18 years) can self-
admi nister while under supervision of HCPs or caregiver/guardian. If subject/parent do 
not feel confident in performing treatment administration at home they are still allowed 
to receive stud y treatment administration at site.
Placebo group : Placebo secukinuma b (one/two s.c. injections per dose) once per week 
for four weeks (at Randomization, Weeks 1, 2 and 3), followed by [CONTACT_121920] (Weeks 4 and 8). Subjects and the efficacy  assessor will be blinded as regards to 
treatment assignment. At Week 12, subjects in the placebo group based on their PASI 
75 response status at Week 12 will proceed as follows:
PASI 75 responders on placebo will discontinue study  treatment at Week 12 and 
enter the treatment -free follow -up epoch for 8 weeks or until systemic therapy 
begins 
PASI 75 non-responders on placebo will receive high dose or low dose 
secukinumab, according to the pre-assignment at the Randomization visit, and 
receive their treatment according to the weight category  based on the weight 
measured at Week 12 visit (<25 kg, 25 -<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, 
and then every  four weeks starting at Week 16 until Week 48 during the 
maintenance epoch; thereafter Week [ADDRESS_136927] or b y caregiver. Subjects <[ADDRESS_136928] not self-administer. However, adolescents (aged 12 to <18 years) can self-
administer while under supervision of HCPs or caregiver/guardian. If 

[COMPANY_001] Confidential Page 39
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
subject/parent do not feel confident in performing treatment administration at 
home they  are still allowed to receive study  treatment administration at site.
5.3 Treatment assignment, randomization 
At Randomization (Visit 2), all eligible patients will be randomized via Interactive Response 
Technology  (IRT) to one of the treatment arms. The qualified site personnel will contact [CONTACT_121921]/exclusion criteria. The subject 
number, the weight of the subject and the age will be entered. The IRT will assign a 
randomization number to the patient. For the subjects who will receive secukinumab or 
secukinumab placebo, this number will be used to link the patient to a treatment arm and will 
specify  a unique medi cation number for the package or packages of investigational treatment 
to be dispensed to the patient. Each subject will receive one or two packages per dispensing 
visit, depending on the treatment group and treatment epoch. For those subjects who will be 
randomized to etanercept, medication will be provided centrally (b y a CRO) or purchased from 
the local market. The randomization number will not be communicated to the caller or other 
site members.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by [CONTACT_6609] a validated system that automates 
the random assignment of patient numbers to randomization numbers. These randomization 
numbers are linked to the different treatment arms, which in turn 
are linked to medication 
number (for the secukinumab and the secukinumab placebo treatment arms). A separate 
medication list will be produced by [CONTACT_121922] y 
Management using a validated system that automates the random assignment of medication 
numbers to packs containing the investigational drug(s). 
Stratification
Randomization will be stratified by [CONTACT_121923]. This 
stratification ensures balanced allocation of subjects to treatment groups within the age and 
weight strata. 
The age strata is “age < 12”or “age ≥12”. The weight strata will be “bod y weight < 25 kg”, 
“25 k g ≤body  weight < 50 kg” or “bod y weight ≥50kg”. Stratification by [CONTACT_121924]. For the randomization at Randomization Visit, it will 
be targeted to have at least approximately  30% of the subjects in e ach weight stratum.
The randomization scheme for subjects will be reviewed and approved b y a member of the IQS 
Randomization Group.
Within each weight stratum, subjects will be assigned to the high dose or the low dose treatment 
group for secukinumab or pl acebo (see Table 5 -1). 
5.4 Treatment blinding 
The secukinumab and the placebo arms are double blind (patient, investigator and assessor) 
until the data base lock for Week 52 analy sis. However, for placebo PASI  75 responders 

[COMPANY_001] Confidential Page 40
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
unblinding will occur at Week 12, since these subjects cannot continue into the Maintenance 
period but need to enter the post treatment follow- up period. 
The etanercept arm is single (assessor) blind until the moment subjects complete the Week 52 
visit and enter the follow -up period. Site staff (with the exception of the efficacy  assessor), 
subject and sponsor are not blinded to the Etanercept arm for the entire treatment duration with 
Etanercept.
Any interim data analy ses for the DMC o r any other interim anal yses which may  be requested 
by [CONTACT_121925]. Unblinded data will only be made available to independent 
[COMPANY_001]/CRO individuals involved in the preparation of the interim analy ses and who are not 
directly  involved in the study  conduct. 
Secukinumab and placebo treatment arms 
Subjects, investigator staff, and data analysts will remain blinded to the identity  of the treatment 
from the time of randomization, using the following methods: (1) Randomization data will be 
kept strictly  confidential until the time of unblinding, and will not be accessible by [CONTACT_121926] , (2) the identity  of the placebo and secukinumab   in prefilled syringes will 
be concealed b y the use of study  drugs that are all identical in packaging, labeling, schedule of 
administration, appearance, and odor. 
Subjects on secukinumab arms, or those who were on placebo arm in induction and PASI [ADDRESS_136929] the data 
base lock for the next interim analysis at Week 24.The detailed procedures will be described 
in a separate charter. 
After the interim database lock for the anal ysis at Week 24, designated Sponsor team members 
will be unblinded, whereas as mentioned earlier the subjects, investigator staff and persons 
performing the assessments will remain blinded until the database lock at Week 52.
Etanercept arm
Person(s) performing efficacy  assessments will remain blind to the identity  of the treatment 
from the time of randomization until Week 52 visit of a patient, using the following methods: 
(1) Randomization data will be strictly c onfidential until the time of unblinding and will not be 
accessible by  [CONTACT_121927] , (2) etanercept treatment will be dispensed and 
administered by [CONTACT_121928] (3) the efficacy  assessor 

[COMPANY_001] Confidential Page 41
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
will not speak to the subject or parent or other site personnel for stud y matters other than those 
associated directly  with the performed efficacy  assessments.
All treatment arms
For all treatment groups, unblinding of site personnel during the induction and the maintenance 
epochs other than described above will onl y occur in the case of subject emergencies.
At the time of the interim evaluation of the data from the first 80 adolescent subjects by [CONTACT_121929] (DMC), designated Sponso r personnel (other than the 
study  team) involved with the interim anal yses will be unblinded.
After the Week 52 database lock (start of open label extension treatment), all subjects, sponsor 
team members, site personnel and persons performing the assessmen ts will be unblinded for all 
treatment arms. 
 
 
The appropriate personnel from the study  site and [COMPANY_001] will assess whether study treatment 
should be discontinued for an y subject whose treatment code has been broken inadvertently for 
any reason. Study  treatment must be discontinued after emergency  unblinding.
5.[ADDRESS_136930] number 1, 
and subsequent subjects are assigned consecutive numbers (e.g. the second subject is assigned 
subject number 2; the third subject is assigned subject number 3). The investigator or his/her 
staff will contact [CONTACT_121930]. The site should select the CRF book with a matching Subject 
Number from the O C/RDC sy stem to enter data.
If the patient fails to be treated for any reason, the IRT must be notified within 2 day s that the 
patient was not treated. The reason for not being treated will be entered on the Screening Epoch 
Study  Disposition CRF.

[COMPANY_001] Confidential Page 42
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
5.5.2 Dispensin g the investigational treatment
Secukinumab and Secukinumab placebo
Each stud y site will be supplied by [CONTACT_121931]. The secukinumab active and placebo treatment packaging 
has a 2-part label. A unique medication number is printed on each part of this label. 
At all visits where secukinumab active and/or placebo is dispensed, the IRT system will allocate 
a medication number which will be transmitted to the pharmacist (or other qualified site 
personnel) responsible for dispensation of study  treatments. The pharmacist (or other qualified 
site personnel) will then identify  the study  treatment package(s) to administer to the subject 
corresponding to the medication number(s). Immediate ly before preparation of the study 
treatment, the pharmacist (or other qualified site personnel) will detach the outer part of the 
label from the packaging and affix it to the source document (Drug Label Form) 
for that 
subject’s unique subject number. Thes e documents will be kept in a secured location as 
appropriate. The study  treatment will be administered by [CONTACT_57012]/ qualified site personnel 
individual.  
During the COVID- 19 pandemic or similar major health care disruption that limits or prevents 
on-site study  visits, delivery  of stud y drug directly  to a subjects ’s home is generall y permitted 
in the event the Investigator has decided that an on-site visit by [CONTACT_121932], and that it is in the interest of the subject ’s health to administer the 
study  treatment even without performing an on
-site visit. The dispatch of study  drug from the 
site to the subject ’s home remains under the accountability  of the Investigator.  
At the site level, the agreement with approval of t he Principal Investigator, Independent Ethics 
Committee/ Institutional Review 
Board (IEC/IRB) and any other Board as appropriate should 
be in place to implement home delivery .
Home administration of secukinumab and secukinumab placebo
After Week 52, subjects will be expected to perform home administrations of secukinumab or 
secukinumab placebo Pre-filled Sy ringe ( PFS)at the protocol specified time points, when they  
are not visiting the site for other trial related procedures . Subjects/ custodians will be previousl y 
trained by [CONTACT_121933], secukinumab/placebo . Only 
adolescent subjects ≥ 12 years and <[ADDRESS_136931] under HCPs or 
caregiver/guardian supervision. 
If the subjec t or custodian is not confident to administer medication at home he/she should visit 
the site every [ADDRESS_136932]/ qualified site personnel will dispense, via IRT, an appropriate 
number of investigational treatment packages for home administrations and detach outer part 
of the label from the packaging as indicated above. The subjects will record the date(s) of 
administration at home and will return the used PFS and packaging at their next visit to the site. 

[COMPANY_001] Confidential Page 43
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Site staff are to transcribe this information into the appropriate Dosage Administration Record 
eCRF.
The used PFS should be disposed immediately  after use in a sharps container OR according to 
the requirements of the respective countries and brought back to site. Subjects will be asked to 
return all unused medication the latest at the completion of the study  or at the time of 
discontinuation of the investigational treatment. Detailed instructions will be provided 
separately .
Etanercept (Enbrel®)
Etanercept (Enbrel®) will be either provided centrally  via a CRO or by [CONTACT_121934]. Etanercept will be provided locally  with support as needed by [CONTACT_121935] (CPO). 
Etanercept should be dispensed as described in the Instruction s for use/package leaflet. As per 
label, the quantity  of the etanercept to be administered to pediatric subjects is dependent on 
their weight. Subjects will receive weekl y s.c. dose of 0.8 mg/kg (up to a maximum of 50 mg) 
The pharmacist will receive from the study  coordinator / study  nurse the weight of etanercept 
subjects in all study  visits where the weight assessment is performed. Based on the weight of 
the patient, the pharmacist will prepare a dispensation sheet containing at a minimum, study  
identific ation, subject number, the weight of the subject, the etanercept form to be administered, 
date and the amount of drug (volume) the patient will need to receive. It will be dated and signed 
by [CONTACT_121936]. This sheet will be filed in a secure place with other drug related 
documentation. A copy of it will be provided together with the etanercept medication to the site 
staff, who is going to administer the medication to the subject. Alternatively if etanercept 
administration will occur at home a copy of it will be handed to the subject/custodian or trained 
nurse/caregiver. Detailed instructions will be provided separatel y.
Home administration of Etanercept (Enbrel®)
Alternativel y, outside of the scheduled site visits, weekly  etanercept medication can be 
admi nistered at home by [CONTACT_1130], trained custodian or trained nurse /caregiver. The first dose of 
etanercept should be administered at the site under the instruction/supervision of the qualified 
site staff. Qualified site staff will provide the subjects/custodians trained nurse/caregiver with 
appropriate training and necessary  instructions as applicable to their local regulations.
Etanercept administration must follow the instructions for use as described in the package 
leaflet and the volume administered will be stated in the etanercept dispensation sheet, as 
prepared by [CONTACT_32335]. Each dose, taken home will be documented appropriatel y by [CONTACT_1560]/custodian or trained nurse/caregiver. Site staff will transcribe this information into the 
appropriate Dosa ge Administration Record eCRF. Detailed instructions will be provided 
separately .
Subjects should be instructed on proper storage, transport of the treatment, as well as about the 
disposal of used sy ringes. Sharps containers will be provided for subjects t o transport the used 
syringes back to the site at frequent intervals for proper disposal. Detailed instructions will be 
provided separatel y.  

[COMPANY_001] Confidential Page 44
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
5.5.[ADDRESS_136933] at the end of the 
study  or at the time of discontinuation of study treatment.
[IP_ADDRESS] Handling of investigational treatment 
Investigational treatment (secukinumab and secukinumab placebo prefilled syringes) must be 
received by  [CONTACT_121937], handled and stored safely  and properly , and 
kept in a secured location. Upon receipt, all investigational treatment should be stored according 
to the instructions specified on the labels. Clinical supplies are to be dispensed only in 
accordance with the protocol. Technical complaints are to be reported to the respective [COMPANY_001] 
CPO Quality  Assurance.
Medication labels for secukinumab and secukinumab placebo prefilled syringes will be in the 
local language and comply  with the legal requirements of each country . They  will include 
storage conditions for the investigational treatment but no information about the patient except 
for the medication number. They  must be stored in a secured refrigerator at 2-8°C (36-46°F), 
and must be carefull y controlled in accordance with regulations governing investigational 
medicinal products and local regulations. Study  treatments should not be frozen. 
[IP_ADDRESS] Handling of other study treatment 
Etanercept will be provided either centrall y or obtained from local market and will be stored 
and handled according to the conditions mentioned in the package leaflet by  [CONTACT_3455]. 
It must be carefully  controlled 
in accordance with regul ations governing investigational 
medicinal products and local regulations. 
Any labelling of etanercept for use by [CONTACT_121938].
5.5.[ADDRESS_136934] be followed.
It needs to be noted that site staff other than efficacy  assessor(s) will be unblind ed regarding 
which subject receives investigational drug (secukinumab or secukinumab placebo) which 
receives active comparator (etanercept). They  will not be aware regarding who is receiving 
active secukinumab and who is receiving placebo.  
The first study treatment administration will occur at the Randomization Visit, after all study 
scheduled assessments have been performed (and inclusion/exclusion criteria confirmed) and 

[COMPANY_001] Confidential Page 45
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
only after the scheduled blood samples have been drawn. Similarly , at each other visit, all study  
assessments should be completed prior to the administration of study  treatment.
During the induction epoch for the secukinumab or secukinumab placebo treatment groups the 
number of injections in total will be:
For the weight group <25 kg:  6 injections 
For the weight groups 25 to <50kg and ≥50kg : 12 injections
During the maintenance epoch for the secukinumab treatment group the number of injections 
in total will be:
For the weight group <25 kg: 13 injections 
For the weight groups 25 to <50kg and ≥50kg : 26 injections
During the extension epoch for the secukinumab treatment group the number of approximate 
injections in total will be:
For the weight group <25 kg:  46 injections 
For the high dose weight groups 2 5 to <50kg and ≥50kg: 92 injections 
For the low dose weight groups 25 to <50kg and ≥50kg: between 46 -92 injections*
* [ADDRESS_136935] to 
receive the minimal amount of injections aligned with the required etanercept dose to be 
administered
All kits of investigational treatment assig ned by [CONTACT_6606] (for secukinumab and secukinumab 
placebo) will be recorded/data -based in the IRT.
The investigator should promote compliance by [CONTACT_121939]. 
Similarly , for home administration of study  drugs (etanercept; secukinumab or secukinumab 
placebo in extension treatment epoch) compliance can be promoted by [CONTACT_121940] d by [CONTACT_121941] y for 
the subject’s safet y and the validity of the stud y. The subject should be instructed to contact [CONTACT_121942]/she is unable for an y reason to take the study treatment as prescribed. 

[COMPANY_001] Confidential Page 46
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Administration of secukinumab/secukinumab placebo
Secukinumab Solution for Subcutaneous Injection (active or placebo, respectivel y) will be 
provided in Prefilled s yringes (75 mg/0.5 mL and 150 mg/mL). 
The study  treatment solution must be injected into non -affected areas of the skin.
If possible, throughout the trial, the study  treatment should be administered to body  regions, 
changing the injection site from visit to visit, for example: right thigh, left thigh, right abdominal 
area, left abdominal area.
Single prefilled s yringes will be packed in individual boxes. The boxes containing the syringes 
with study  treatment solution should be kept at 2 to 8°C (36°F and 46°F) and protected from 
light. They  should not be frozen or shaken. Prior to administration the boxes containing the 
syringes with study  treatment solution should be allowed to come to room temperature 
unopened for about 15-30 minutes before administration. Used syringes should be disposed 
immediately  after use in a sharps container or according to the requirements of the respective 
countries. For home administration please refer to Section 5.5.2.  
Note: The removable cap of the secukinumab pre -filled syringe 1 mL and 0.5mL form contains 
a derivative of natural rubber latex. Although no natural rubber latex is detected in the cap, the 
safe use of the secukinumab 1 mL or 0.5 mL pre-filled syringe in latex -
sensitive individuals has 
not been studied.
Administration of Etanercept
Etanercept medication will be administered as described in the local instructions for 
use/package leaflet (see also Section 5.5.2)
Etanercept medication can be administered either at site or at home. The preferred option would 
be the home administration and should be encouraged and facilitated by  [CONTACT_779]. The decision 
nevertheless remains with subject/custodian. Depending on local capabilities, study  personnel 
or trained nurse /caregiver should also be considered to administer the Etanerce pt medication 
at the subject’s home. Qualified site staff will discuss all options with the subject/custodian and 
support their decision.
For subjects who opt for home administration, at each site visit commerciall y available 
etanercept medication will be handed. The amount of medication should be sufficient to cover 
the time period until the next scheduled site visit with surplus medication to cover for eventual 
misuse or malfunctioning of etanercept s yringe or for delay in presenting to the next visit.
For more information about home administration refer to Section 5.5.2.
Note: The needle cover of the pre -filled Etanercept syringe and pens contains latex (dry natural 
rubber) that may cause hypersensiti vity reactions when handled by, or 
when Etanercept is 
administered to, persons with known or possible latex sensitivity . The majority  of Etanercept 
patients in this study  are expected to use the 25 mg powder for solution for injection rather than 
the prefi lled s yringe or pen. 
5.5.5 Permitted dose adjustments and interruptions of study  treatment
No dose adjustments or interruptions are permitted.

[COMPANY_001] Confidential Page 47
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
5.5.6 Rescue medication 
Rescue medication for psoriasis is not permitted in this study .
5.5.7 Prior and Concomitant treatment 
Relevant treatments (excluding those for psoriasis) taken within [ADDRESS_136936] started to treat psoriasis will be reported 
on the Prior psoriasis therapy  eCRF and not in the Prior and Concomitant Medications eCRF. 
This includes all topi[INVESTIGATOR_12969], systemic treatments and phototherapi[INVESTIGATOR_121877] (Section 6.2.2). Any treatment used to treat a 
symptom of psoriasis but 
not the condition itself should not be entered on the Prior Psoriasis 
Therapi[INVESTIGATOR_50061] (e.g., enter antihistamine or bland emollient in the concomitant medications 
eCRF and enter anynon-medicated intervention in the Procedures and Non-drug therapi[INVESTIGATOR_121878]). 
Topi[INVESTIGATOR_11930] (TCS) must be recorded in the concomitant medications TCS eCRF. 
Start date, end date, dose, unit, frequency , route and reason for administration or change are to 
be recorded (see Section [IP_ADDRESS].).
The investigator should instruct the patient to notify  the study  site about any new medications 
he/she takes after the patient was enrolled into the study . Allmedications, procedures and 
significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered 
after the patient was enrolled into the study  must be recorded
[IP_ADDRESS] Permitted concomitant medications (not for psoriasis or psoriatic 
arthritis)
Concomitant medications are allowed if not listed in Table 5-2. Dose adjustments of these 
medications should be avoided during the study . If a dose adjustment of these medications does 
occur, they must be recorded on the Prior and Concomitant medications eCRF or the Procedures 
and Significant non -drug therapi[INVESTIGATOR_14932].
Subjects who are receiving treatments known to worsen psoriasis (e.g. beta-blockers) must be 
on stable dose for at least 4 weeks before Randomization Visit.
TCS and other topi[INVESTIGATOR_121879] 12 visit and until the end of study  
only if:
medication was started after the week 12 visit was completed;
medication was used for 14 consecutive calendar day s or less;
medication was used for an indication other than psoriasis and noton the area affected with 
psoriasis.  
Use of these TCS must be recorded on the Concomitant medications TCS eCRF. 

[COMPANY_001] Confidential Page 48
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
There is no restriction on the use of anti-histamines or of corticosteroid drops used in the eye 
or ear during the study
[IP_ADDRESS] Permitted concomitant medication for psoriasis
After the screening period, the use of concomitant medication for psoriasis in all body  regions 
is restricted to bland emollients (not supplied by [CONTACT_5343]) and other non-medicated 
interventions (not listed in Table 5-2). Use of bland emollients must be recorded on the Prior 
and Concomitant medications eCRF. Use of any other non-medicated interventions must be 
recorded on the Procedures and Significant non- drug therapi[INVESTIGATOR_14932].
The definition of “bland” excludes all topi[INVESTIGATOR_121880] (but not limited to) lactic acid, salicy lic acid, urea, α -hydroxy  acids or fruit 
acids.
Once the subject is screened and if the subject has intolerable scaling and/or itching, the use of 
bland emollients is permitted. The use of bland emollients should be avoided during the 12 
hours preceding a scheduled study  visit. 
A topi[INVESTIGATOR_19529] l corticosteroid (CS) treatment of mild or moderate activity  is allowed for the face, 
scalp ,hands, feetand genitoanal area during the screening period, but not after the subject has 
been randomized. These topi[INVESTIGATOR_121881] [ADDRESS_136937] be recorded on the Prior psoriasis 
therap y eCRF if used to treat psoriasis. If not used to treat psoriasis it should be entered in the 
TCS eCRF ( Section [IP_ADDRESS]).
5.5.[ADDRESS_136938] 
to notify  the study  site about any newtreatments 
he/she takes after the start of the study  treatment. All prohibited medications and significant 
non-drug therapi[INVESTIGATOR_121882] -
drug therapi[INVESTIGATOR_121883].  
If a prohibited treatment listed in Table [ADDRESS_136939] 
discontinue use of the prohibited treatment if he/she wishes to continue in the study . At the 
discretion of the investigator, if the subject’s use during the study  of a prohibited treatment 
listed in Table [ADDRESS_136940] discontinue study  treatment.
During the screening period, subjects will be allowed to use some active topi[INVESTIGATOR_121884]: face, scalp, hands, feet and genitoanal area. The 

[COMPANY_001] Confidential Page 49
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
active topi[INVESTIGATOR_121885]: mild or moderate potency  CS. The subject must stop 
use of these topi[INVESTIGATOR_121886] [ADDRESS_136941] ies for all active topi[INVESTIGATOR_121887] y indication ( Table 5 - 2).
The Sponsor will be notified if a prohibited treatment is taken while the subject is on study .
Table 5-2 Prohibited treatment
Prohibited Treatment Wash-out period up 
to RandomizationInduction 
Epoch1,2Maintenance 
Epoch1,2Open label Epoch1,2
Alefacept, briakinumab, 
efalizumab, ustekinumab26 weeks Not allowed Not allowed Not allowed
Biological immunomodulating 
agents other than above (e.g., 
adalimumab, infliximab)12 weeks Not allowed Not allowed Not allowed 
Etanercept No prior use 
allowed 
Other systemic 
immunomodulating treatments
(e.g., MTX, cyclosporine A 
[CSA], corticosteroid, 
cyclophosphamide)4 weeks Not allowed Not allowed Not allowed 
Photochemotherapy (e.g., 
PUVA) 4 weeks Not allowed Not allowed Not allowed
Other systemic therapy for 
psoriasis (e.g., retinoids, 
fumarate )4 weeks Not allowed Not allowed Not allowed
Any other investigational 
treatment or participation in 
any interventional trial4 weeks or 5 half -
lives (whichever is 
longer)Not allowed Not allowed Not allowed
Phototherapy (e.g., UVA, UVB) 2 weeks Not allowed Not allowed Not allowed
Topi[INVESTIGATOR_35786]3for psoriasis 
or any other skin condition 
(e.g., corticosteroids, vitamin D 
analogues, pi[INVESTIGATOR_031], 
retinoids, salicylvaseline, 
salicylic acid, lactic acid, 
tacrolimus, tar, urea, α -hydroxy 
or fruit acid s), except on the 
face, scalp, hand and feet and 
genitoanal area during 
screening2 weeks4Not allowed Not allowed5Not allowed5
Live virus vaccinations [ADDRESS_136942] discontinue use of the 
prohibited treatment if he/she wishes to continue in the study. 
2.In case of undue safety risk for the subject, the subject should discontinu e study treatment at the discretion of 
the investigator. 
3.Including intra -articular or peri -articular injections. Note that inhaled corticosteroids as well as corticosteroid 
drops in the eye or ear or nasal sprays are permitted. 
4.Mild to moderate topi[INVESTIGATOR_2855] c orticosteroids are allowed only during the screening period if used only on the face, 
scalp, hands and feet and/or genitoanal area and if not used during the 12 h preceding the randomization 
visit

[COMPANY_001] Confidential Page 50
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
5.Topi[INVESTIGATOR_121888] (all must apply):
medication was started after the W eek 12 visit was completed;
medication was used for 14 consecutive calendar days or less;
medication was used for an indication other than psoriasis and not on the area affected with psoriasis
6.If the subject received a live virus vaccination during the study, the subject must discontinue study treatment.
Exposure to light
Subjects need to be advised to limit exposure to ultraviolet (UV) light (including sunbathing 
and/or use of UV tanning devices) during the study  to avoid possible effect on psoriasis
5.5.[ADDRESS_136943] be discontinued under the following circumstances: 
Subject’s wish 
Withdrawal of consent
If the investigator/qualified site staff believe that for a given subject continuation of the 
study  treatment would be detrimental to the subject’s well -being.
Emergence of the following AEs: AEs that in the judgment of the investigator/qualified 
site staff, taking into account the subject’s overall status, prevent the subject from 
continuing study  treat ment for example sepsis or newly  occurring or worsening 
Inflammatory  Bowel Disease, including Crohn’s disease and ulcerative colitis . 
Any laboratory  abnormalities that in the judgment of the investigator/qualified site staff, 
and taking into consideration the subject’s overall status, prevents the subject from 
continuing study  treatment. 
Any requirements met for liver events or liver laboratory  value triggers as described in 
Appendix 2 , Table 14-2
Any requirement met for renal events as described in Section 7.4
Live virus vaccination
Pregnancy  (see Section 6.5.8 and Section 7.5) 
Ongoing use of prohibited treatment as per recommendations in Section 5.5.8. 
Emergency  unblinding.
Any protocol deviation that results in a significant risk to patient’s safet y
If discontinuation occurs for any reason in a treatment epoch, the investigator/qualified 
site staff 
must make every effort to determine the primary  reason for a subject’s discontinuation from the 
study .  This information will then be recorded by [CONTACT_1697]/qualified site staff on the 
applicable end of study  epoch eCRF.
Subjects discontinued from study  treatment will NOT be considered discontinued from the 
study . On the applicable end of treatment epoch eCRF (EOI, EOM, and EOT completion 

[COMPANY_001] Confidential Page 51
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
eCRFs), the investigator/qualified site staff must record the date and primary  reason for 
stoppi[INVESTIGATOR_79558]. 
At the time of the study  treatment discontinuation visit, if it has been approximately  [ADDRESS_136944] dose of study  treatment then the assessments described EOI Visit Week 12 (for early 
discontinuation during induction epoch) or EOM Visit Week 52 (for early  discontinuation 
during maintenance epoch) or EOT Visit Week 236 (for early discontinuation during extension 
epoch) should be completed at this visit. 
If it has not been approximately  [ADDRESS_136945] dose for their EOI, EOM or EOT visit as appropriate.
The investigator/qualified 
site staff must contact [CONTACT_121943], 
EOM, EOT Visits as appropriate, to register the subject’s earl y completion of the study  due to 
study treatment discontinuation. 
See Section 6 for the required assessments of these subjects after study  treatment 
discontinuation. 
Discontinuation from a treatment -free period
If premature withdrawal occurs for any reason in the treatment -free period (follow up epoch, 
Week 240 -Week 252), the investigator must make every effort to determine the primary reason 
for a subject’s premature withdrawal from the study  and record this information on the 
applicable end of study  period eCRF (Follow up  epoch completion eCRF EOF, Visit Week 
252 (F16)). Of note, if subjects start another s ystemic anti psoriatic treatment during follow up, 
they do not need to continue with the remaining follow -up visits but they will be expected to 
return to site after the start of the systemic treatment and perform End of Follow -up (EOF) visit.
See Section [ADDRESS_136946]:
Does not want to participate in the study  anymore, and
Does not allow 
further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_5366]-up.

[COMPANY_001] Confidential Page 52
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. 
[COMPANY_001] will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicable 
law.
For US and Japan: All biological sa mplesnot y et anal yzed at the time of withdrawal may still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by  [CONTACT_1289]. They will be stored according to applicable 
legal requirements.
5.5.11 Loss to follow -up 
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw, the investigator should show "due diligence" by [CONTACT_121944], 
family  or famil y physician as agreed in the informed consent and b y documenting in the source 
documents steps taken to contact [CONTACT_102], e.g. dates of telephone calls, registered letters, etc.
5.5.[ADDRESS_136947] often, study  treatment discontinuation and knowledge of 
the possible treatment assignments are sufficient to treat a study  patient who presents with an 
emergency  condition. Emergency  treatment code breaks are performed using the IRT. When 
the investigator contacts the system to break a treatment code for a patient, he/she must provide 
the requested patient identify ing information and confirm the necessity  to break the treatment 
code for the patient. The investigator will then receive details of the investigational drug 
treatment for the specified patient and a fax or email confirming this information . The system 
will automatically  inform the [COMPANY_001] monitor for the site and the Global Trial Director (GTD) 
that the code has been broken.
It is the investigator’s responsibility  to ensure that there is a procedure in place to allow access 
to the IRT/code break cards at any  time in case of emergency . The investigator will inform the 
patient orally and in written how to contact [CONTACT_5657]/her backup in cases of emergency  or when he/she 
is unavailable, to ensure that un-blinding can be performed at any time. The investigator will 
provide protocol number, study  treatment name [CONTACT_121993].
The appropriate personnel from the study  site and [COMPANY_001] will assess whether study treatment 
should be discontinued for an y subject whose treatment code has be en broken inadvertently  for 
any reason.
Study  treatment must be discontinued after emergency  unblinding. 
Subjects, who are prematurely  unblinded and are discontinued from study  treatment, will be 
requested to return for the applicable end of period visit 
(EOI Visit Week 12 or the EOM Visit 
Week 52 or Week 236 EOT) and the four follow -up visits (Visits Week 240, Week 244, Week 

[COMPANY_001] Confidential Page 53
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
248 and Week 252). If subjects start another s ystemic anti psoriatic treatment during follow up, 
they do not need to continue with the remaining follow -up visits but they will be expected to 
return to site after the start of the systemic treatment and perform End of Follow -up (EOF) visit. 
5.5.[ADDRESS_136948] occurs when the End of Follow -up visit (EOF) 
has been performed as per protocol. For a discontinued subject study  completion corresponds 
to the last study  visit of the patient or contact [CONTACT_121945]/her.  Study completion for the 
study  will occur when all s ubjects who have been randomized will have completed the study as 
stated above. 
The investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care. 
5.5.14 Early  study termination 
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible and be treated as a prematurely  discontinued 
patient (see Section 5.5.9). The investigator may be informed of additional procedures to be 
followed in order to ensure that adequate consideration is given to the protection of the patient’s 
interests. The investigator will be responsible for informing the Institutional 
Review 
Board/Independent Ethics Committee (I RBs/IECs) of the earl y termination of the trial.
Subjects who prematurely discontinue study  treatment for any reason should be scheduled for 
an End of Induction (EOI) or End of Maintenance (EOM) or End of treatment (EOT) visit as in 
Table 6-1and Table 6-2. If the subject is unable to return for the EOI or EOM or EOT visits, 
every  effort sho uld be made to contact [CONTACT_121946] y related 
information (primaril y AEs) during the [ADDRESS_136949] the patient should be recorded in the source documents.
6 Visit schedule and assessments
Subjects should be seen for all visits on the designated day or as closely  as possible to the 
original planned visit schedule .
During the COVID -
19 pandemic or similar major health care disruption which limits or 
prevents on-site study  visits, alternative methods of providing continuing care may be 
implemented such as phone 
calls, virtual contacts (e.g. teleconsult) or visits by [CONTACT_121947] a 
home nursing service to the subject ´s home depending on local regulations and capabilities, that 
can partially  replace on -site study  visits, for the duration of the pandemic until it is safe for the 
subject to visit the site again. These contacts should occur on or around the scheduled visit dates 
(or more frequentl y if needed). Every effort should be made to complete all study  visit 
assessments feasible per protocol. Special effort should be made to conduct the scheduled EOT 
and EOF visits on site. If it is not feasible to conduct these visits on- site, at lea st phone contact 
[CONTACT_121948], visits to the subject ´s home by [CONTACT_121949].

[COMPANY_001] Confidential Page 54
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Screening will be flexible in duration and will last up to a maximum of [ADDRESS_136950] sall of the assessments and indicates with an “x” at which visits the 
assessments are performed. 
If for any reason the subject is a screen failure, the subject may be rescreened. There is no 
restriction on the number of times a potential subject may be rescreened or on how much time 
must pass from the date of screen failure and the date of rescreening.
Ifa subject rescreens for the study , then the subject must sign a new ICF and be issued a new 
subject number prior to any screening assessment being conducted for the subject under the 
new screening subject number. For all subjects, the investigator/qualified site staff will record 
if the subject was rescreened on the rescreening CRF and any applicable screening numbers the 
subject was issued prior to the current screening number.
The date of the new informed consent signature [CONTACT_109061]. Informed Consent for a rescreened subject 
must be obtained prior to performing any study related assessment or collecting any data for the 
Screening Visit. For rescreening, all screening assessments must be performed as per protocol, 
except for the tuberculosis (TB) work up, if applicable, if performed not more than [ADDRESS_136951] performed by  [CONTACT_2237] .
At the discretion of the investigator, laboratory  assessments at randomization visit need not to 
be performed if screening laboratory  assessments were performed within 7 days from 
randomization.
During 
the treatment epoch s, subjects may be seen at an unscheduled visit, e.g. if they 
experience deterioration of psoriasis, or AEs that in the opi[INVESTIGATOR_121889]. During these unscheduled visits, study  treatment 
will NOT be administered. The assessment(s) performed at an unscheduled visit are at the 
investigator ’s discretion. 
Suggested order of assessments :
Suggested guidelines for conduct of the visit assessments are below:
Subject to complete CDLQI at the stud y site prior to any stud y assessments 
Parent/custodian (or together with subject if subject is of 18 y ears of age or older) to 
complete childhood health assessment questionnaire, CHAQ©
Efficacy  assessor to complete efficacy  assessments.
1.IGA mod 2011 (all visits)
2.PASI  (all visits)
Investigator to complete investigator assessments
1. Review CDLQI and CHAQ data (at applicable visits)

[COMPANY_001] Confidential Page 55
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
2.Physical exam (at applicable visits)
All remaining stud y visit procedures (e.g., laborator y sample collection, vital signs 
measurements) must be completed prior to study  treatment dosing.
Enter PASI  data into the source data worksheets and perform calculations as needed 
BEFORE contact[CONTACT_121950] 12 Visit.
Contact I RT to re gister the subject visit, as applicable
Administration of study  treatment, as applicable

[COMPANY_001] Confidential Page 56
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Table 6-1 Visit and assessment schedule for the Blinded Epoch
Epoch Scr Induction Epoch Maintenance Epoch
Visit 1 2 3 4 5 6 7 8a
E
OI9 10 11 12 13 14 15 16 17 18 19 20 21b
EO
M
Week-4-R* R 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Day
-28-R* [ADDRESS_136952] demographics x
Inclusion/exclusion2S S
Psoriasis history/prior therapi[INVESTIGATOR_014] x
Medical history and prior 
medicationsx
Concomitant medications3x x x x x x x x x x x X x x x x x x x x x
Surgeries and  non -drug 
proceduresx x x x x x x x x x x X x x x x x x x x x
Physical Exam S S S S S S S S S S S S S S S S S S S S S
Height4x x x x x X x x x x x x x x x
Weight x x x x x X x x x x x x x x x
Vital signs (BP & pulse) x x x x x x x x x x x X x x x x x x x x x
Labs: Hematology6x x x x x x x X x x x x x x x x x
Blood chemistry6, Urinalysis 
(local) x x x x x X x x x x

[COMPANY_001] Confidential Page 57
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Epoch Scr Induction Epoch Maintenance Epoch
Visit 1 2 3 4 5 6 7 8a
E
OI9 10 11 12 13 14 15 16 17 18 19 20 21b
EO
M
Week-4-R* R 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Day
-28-R* 1 8 15 22 29 57 85 92 99 106 113 141 169 197 225 253 281 309 337 365
Renal monitoring (conditional) 
Urinalysis, Urine Microscopy, 
Fasting Glucose. 6, 7x x x X x x x x x x x x x
Tuberculosis test8x
Pregnancy test (in females of 
childbearing potential) 6,[ADDRESS_136953] X ray (optional) 10x
ECG (standard 12 -lead) x x x x
PASI x x x x x x x x x x x X x x x x x x x x x
IGA mod 2011 x x x x x x x x x x x X x x x x x x x x x
CDLQI 12x x x x x x x
CHAQ©(for subjects with History 
of Psoriatic Arthritis only)x x x x x x x
Adverse event assessment x x x x x x x x x x x X x x x x x x x x x
SAE assessment x x x x x x x x x x x X x x x x x x x x x
Randomization via IRT 13x
Data entry of weight into IRT14x x x x x X x x x x x x x x x

[COMPANY_001] Confidential Page 58
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Epoch Scr Induction Epoch Maintenance Epoch
Visit 1 2 3 4 5 6 7 8a
E
OI9 10 11 12 13 14 15 16 17 18 19 20 21b
EO
M
Week-4-R* R 1 2 3 4 8 12 13 14 15 16 20 24 28 32 36 40 44 48 52
Day
-28-R* 1 8 15 22 29 57 85 92 99 106 113 141 169 197 225 253 281 309 337 365
Administration of study drug 
(double blind: secuk/placebo)x x x x x x x x x x X x x x x x x x x
Dispense etanercept 15S S S S S S S S S S S S S S S S S S S
End of induction eCRF 
completion x
End of maintenance eCRF 
completionx
Contact [CONTACT_54537]/IW RS x x x x x x x x x x x X x x x x x x x x
R=Randomization, ECG=Electrocardiograms, CDLQI= children’s dermatology life quality index, SAE=serious adverse events, 
IRT=Interactive response technology, EOI -End of induction, EOM -End of Maintenance.
X=assessment entered or transferred into the clinical database. S= assessment only recorded in source .
*Before randomizing the subject, the site must ensure that all asses sments of the screening visit have been performed, all lab results are available and 
subject is eligible. Special attention must be given to tuberculosis testing as results take longer to be available .
a During Week [ADDRESS_136954] assessments performed for the maintenance epoch (EOM) and will enter the o pen-label extension 
treatment epoch.  
1There are two types of i nformed consent for this study, the general informed consent/assent  
2 These assessments are supported by [CONTACT_121951]. However, data regarding to which inclusion/e xclusion criteria are 
met are captured on the Inclusion/Exclusion screen eCRF .

[COMPANY_001] Confidential Page 59
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
[ADDRESS_136955] may  use, is entered in the Concomitant medications -topi[INVESTIGATOR_121890]
4  Measured standing and barefoo t, using the same calibrated stadiometer. 
    
6 Samples will be shipped to and analyzed by [CONTACT_6626]. At the discretion of the investigator, laboratory assessments nee d not to be performed 
again at Randomization (R) visit if screening labs were performed within 7 days from randomization.
7As part of the renal safety monitoring (details in Section 7.4 ) certain alert conditions may  be fulfil led based on biochemistry and urine dipstick results. As 
a follow up action urine samples (first morning void) must be shipped to central lab for quantitative urinalysis and/or urine microscopy . Similarly, fasting 
glucose analy sis may  be also be required b ased on glucose urine dipstick result.
[ADDRESS_136956] QuantiFERON® TB -Gold In -Tube test is indeterminate, the investigator may  choose to perform a second QuantiFERON® TB -Gold In -Tube 
test (as part of an unscheduled visit) or refer the subject for tuberculo sis workup per local guidelines.  If the result of any QuantiFERON® TB -Gold In -
Tube test is “positive” or the results of 2 sequential QuantiFERON® TB- Gold In -Tube tests are ”indeterminate”, the subject must be referred to have a 
tuberculosis workup per loc al guidelines (if no workup within 12 weeks prior to randomization is available).   The subject will not be eligible for 
randomization if “active tuberculosis is present “or if “latent tuberculosis is present and is untreated as per local guidelines.”  No QuantiFERON® TB -Gold 
In-Tube test is to be done at the central laboratory after the subject has been randomized.
[ADDRESS_136957] started menstruation and/or are of age [ADDRESS_136958] MRI (at prespecified sites) may  be performed based on the investigator’s judgment, to assess presence of 
infections or malignancies .
  
 
12Text only version will be used in all subjects. Assessment will no longer be performed once subjects reach [ADDRESS_136959] be calculated by [CONTACT_121952]/appropriate site staff prior to contact[CONTACT_112785].  The investigator must ensure 
subject meets a ll eligibility criteria before contact[CONTACT_121953].  At Visit 8 (week12), the site should have the PASI 7 5 responder 
status calculated prior to contact[CONTACT_121954].
14For every visit (including unscheduled), weight measure d at that visit will be entered into IRT.
[ADDRESS_136960]/parent does not feel confident in performing study treatment administration at home, they are allowed to receive 
study treatment administration at site. 

[COMPANY_001] Confidential Page 60
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Table 6-2 Visit and A ssessment schedule f or the Extended treatment epoch
Epoch Extension Treatment Epoch Follow -up EpochUnscheduled dVisit 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 End of  
ext. 
treat. 
(EOT)bF4cF8cF12cF16c
EOF
Week 52a64 76 88 104 116 128 140 156 168 180 192 208 220 232 236 240 244 248 252
Day 365 449 533 617 729 813 [PHONE_2775] 1177 1261 1345 1457 1541 1625 1653 1681 1709 1737 1765
Concomitant 
medications1 x x x x x x x x X x X x x x x x x x x x
Surgeries and non -
drug proceduresx x x x x x x x X x X x x x x x x x x x
Physical Exam S S S S S S S S S S S S S S S S S S
Height2x x x x x x x x x x X x x x x x x x
Weight x x x x x x x x x x X x x x x x x x
Vital signs (BP & 
pulse)x x x x x x x x x x X x x x x x x x x x
Hematology4  x x x x x x x x x x X x x x x x x x
Blood Chemistry4, 
Urinalysis (local) x x x x x x x x x x X x x x x x x x
Renal monitoring 5 
(conditional) 
Urinalysis4, Urine 
Microscopy4, Fasting 
Glucose4x x x x x x x x x x X x x x x x x x

[COMPANY_001] Confidential Page 61
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Epoch Extension Treatment Epoch Follow -up EpochUnscheduled dVisit 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 End of  
ext. 
treat. 
(EOT)bF4cF8cF12cF16c
EOF
Week 52a64 76 88 104 116 128 140 156 168 180 192 208 220 232 236 240 244 248 252
Day 365 449 533 617 729 813 [PHONE_2775] [ADDRESS_136961] (in 
females of 
childbearing 
potential) 4,7x x x x x x x x x x X x x x x x x
ECG (standard 12 -
lead)x x x x x x x x
PASI x x x x x x x x x x X x x x x x x x x x
IGA mod [ADDRESS_136962] IVRS/IW RS x x x x x x x x x x x X x x x
Dispensing10
secukinumabx x x x x x x x x x x X x x x

[COMPANY_001] Confidential Page 62
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Epoch Extension Treatment Epoch Follow -up EpochUnscheduled dVisit 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 End of  
ext. 
treat. 
(EOT)bF4cF8cF12cF16c
EOF
Week 52a64 76 88 104 116 128 140 156 168 180 192 208 220 232 236 240 244 248 252
Day 365 449 533 617 729 813 [PHONE_2775] 1177 1261 1345 1457 1541 1625 1653 1681 1709 1737 1765
End of Extension 
Treatment eCRF 
completionx
End of Follow -up 
eCRF completion x
, ECG=Electrocardiogram, CDLQI= children’s dermatology life quality index, SAE=serious adverse events , IRT=Interactive 
response technology, EOI- End of induction, EOM -End of Maintenance, EOT -Endof Extension Treatment ,  EOF -End of Follow -up
X=assessment entered or transferred into the clinical database. S= assessment only re corded in source
a Week [ADDRESS_136963] assessments perform ed for extension treatment epoch  
c Follow -up assessments are  to be conducted for subjects who complete extension treatment epoch and for subjects who discontinue study treatment 
early 
d The assessments performed at an unscheduled visit are at the investigator’s discretion 
1Information on Topi[INVESTIGATOR_121891], that a subject may  use, is entered in the Concomitant medications -topi[INVESTIGATOR_121890]
2 Measured standing and barefoot, using the same calibrated stadiometer, 
   
4 Samples will be shipped to and analyzed by [CONTACT_6626].
5As part of the renal safety monitoring (details in Section 7.4 ) certain alert conditions may  be fulfilled based on biochemistry and urine dipstick results. As 
a follow up action urine samples (first morning void) must be shipped to central lab for quantitative urinalysis and/or urine microscopy . Similarly, fasting 

[COMPANY_001] Confidential Page 63
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
glucose analy sis by  [CONTACT_121955] . Once a subject reaches adulthood ( ≥18 years of age) 
this procedure no longer needs to be followed.
  
 
[ADDRESS_136964] started menstruation and/ or are of age [ADDRESS_136965] (self -injection only for adolescents of at least 12 years of age and under supervision) or by [CONTACT_84452]. In case subject or parent does not 
feel confident in performing home administrations they will be allowed to continue to perform administration at site. These a dministrations should occur at 
Wk 56, Wk 60, W k 68, Wk 72, W k 80, Wk 84, W k 92, Wk 96, Wk 100, W k 108, Wk 112, W k 120, Wk 124, W k 132, Wk 136, W k 144, Wk 148, W k 152, 
Wk 160, Wk 164, W k 172, Wk 176, wk 184, W k 188, Wk 196, Wk 200, W k 204, Wk 212, Wk 216, W k 224 and W k 228.  

[COMPANY_001] Confidential Page 64
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.[ADDRESS_136966] not being randomized will be entere d on the Screening 
Phase Disposition eCRF. The Screening visit date, the Demograph y eCRF, the Informed 
Consent eCRF, the Inclusion/Exclusion eCRF, and the subject rescreening eCRF must be 
completed.  The AE eCRF should be completed for any SAEs that occurr ed during the screenin g 
period. Adverse events that are not SAEs will be followed by [CONTACT_121956]. The Death eCRF should be completed in the case of a death during the 
screening period. The withdrawal of consent eCRF must be completed if consent was 
withdrawn during the screening period before the subject was randomized.
For all subjects who sign the informed consent and entered into the next period of the stud y, all 
AEs occurring after the informed consent is signed will be recorded on the AE eCRF.
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgment, the test abnormality  occurred prior to the inform ed consent 
signature.
6.[ADDRESS_136967] demographics/other baseline characteristics 
All Baseline assessments should be performed prior to first study  treatment administration. 
These may be in the screening period (e.g. demographics) or at the Randomization Visit (e.g. 
PROs), depending on the assessment. 
6.2.1 Demographics
Data to be collected on all patients include: year of birth, age, sex, race, ethnicity , and child-
bearing potential (for females). 
6.2.2 Psoriasis medical history / Previous psoriasis therapy
Disease history will be collected at the screening visit. The information to be collected and 
entered in the Psoriasis History  eCRF and Prior Psoriasis Therapi[INVESTIGATOR_121892]:
The date of first diagnosis of plaque psoriasis (b y a phy sician)
The previous tr eatments of psoriasis (including previous use sy stemic therapi[INVESTIGATOR_014], biologic 
therapi[INVESTIGATOR_014], as well as phototherap y and/or photo chemotherap y or topi[INVESTIGATOR_44785]) and the 
reason for discontinuation of each therap y
The presence of psoriatic arthritis and the date of f irst diagnosis (b y a ph ysician)
6.2.3 Relevant medical history  / current medical conditions 
Relevant medical history and current medical conditions, not including psoriasis or psoriatic 
arthritis, prior to signing of the informed consent will be recorded in the Medical History  eCRF. 
Whenever possible, diagnoses and not sy mptoms will be recorded.

[COMPANY_001] Confidential Page 65
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Significant findings that are observed after the subject has signed the informed consent form 
and that meet the definition of an AE must be recorded in the AE eCRF.
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
6.2.[ADDRESS_136968] X -ray (optional)
Chest X -ray is an optional assessment w hich can be performed in screening at the discretion of 
the investigator, if warranted for the subject. This is aimed to detect ongoing infection and 
particularl y tuberculosis or malignancy.
A chest X-ray (or chest MRI  at pre specified sites) must only be done after it is fairly  certain 
that the subject meets the other inclusion/exclusion criteria, in order to minimize unnecessary 
exposure to X -ray radiation for subjects. 
If the chest X-ray or MRI  evaluated by a qualified physician shows evidence of ongoin g 
infections or malignancy  and the subject was not treated subsequent to the X -ray (or MRI), the 
subject will not be eligible to enter the stud y.
6.2.5 Determination of Tuberculosis status
Determination of tuberculosis (TB) status will be required before adminis tration of study  
treatment and should be performed as defined by [CONTACT_13144]. TB status must be determined 
by [CONTACT_9870] , signs, symptoms and TB testing (QuantiFERON -TB Gold assay). Any 
significant findings will be recorded in the TB assessment eCRF and the Medical History  eCRF, 
as necessary .
QuantiFERON TB -Gold In -Tube assay
A QuantiFERON®TB-Gold I n-Tube assay  (QFT) will be performed to assess the TB status at 
screening for all subjects. This test will only be used to determine subject’s eligibi lity for the 
trial. The test will be used to screen the subject population for latent tuberculosis infection 
(Dohert y 2008 ).
This blood -based assay  is specific for Mycobacterium tuberculosis and is not influenced by 
[CONTACT_37257] -Guérin vaccination or exposure to other Mycobacteria species. This 
test, in contrast to the purified protein derivative ([COMPANY_003]) skin test, is also insensitive to a booster 
effect since the subject is not exposed to the vaccine. The assay  measures the production of 
interferon -gamma and presents it relative to a negative and a positive control sample. Further 
information is available in Manuel and Kumar (2008) .
The QuantiFERON® -TB Gold assay test will be supplied by  [CONTACT_2237] . Details on 
the collection, shipment of samples and reporting of results by [CONTACT_105260].
Refer to Figure [ADDRESS_136969] be recorded on the Tuberculosis 
assessment eCRF.
If the test result is 
negative , the subject may  be randomized.

[COMPANY_001] Confidential Page 66
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
If the test result is positive , the investigator should perform workup for the test result as 
per local procedures. If a TB workup was conducted prior to the screening the subject, 
results of the workup can be used to assess elig ibility  if the workup was conducted within 
12weeks prior to randomization.
Subjects’ positive for latent TB per workup may  be randomized to the trial if sufficient 
treatment has been initiated according to local routine clinical practice and will be 
maint ained for the prescribed duration. Subjects positive for active TB per workup are not 
eligible for the study . Subjects negative for TB (no signs of latent or active TB) per 
workup may  be randomized to the trial.
If the test result is indeterminate , the investigator may repeat the test once or may 
proceed directly to perform workup for the test result as per local procedures. This 
action is at the discretion of the investigator. If a TB workup was conducted prior to the 
screening the subject, results of the workup can be used to assess eligibility  if the workup 
was conducted within 12 weeks prior to randomization. 
If the second test is negative , the subject may  be randomized.
If the second test is positive , the investigator should perform workup as per local
guidelines. Subjects’ positive for latent TB per workup may  be randomized to the trial if 
sufficient treatment has been initiated according to local routine clinical practice and will 
be maintained for the prescribed duration. Subjects positive for active TB per workup are 
not eligible for the study. Subjects negative for TB per workup (no signs of latent or 
active TB) may  be randomized to the trial.
If the second test is again indeterminate , the investigator should perform follow -up for the 
test result as per local procedures. Subjects tested positive for latent TB per workup may  
be randomized to the trial if sufficient treatment has been initiated according to local 
routine clinical practice. Subjects positive for active TB per workup are not eligible for
the study . Subjects negative for TB per workup (no signs of latent or active TB) may  be 
randomized to the trial if the workup was conducted [ADDRESS_136970] result and a TB workup (i.e., no second TB test 
will be performed), the TB test to assess eligibility  must have been done via the central 
laboratory  for the study  within the screening period (within 4 weeks prior to randomization) 
and TB workup will only be considered if it was completed within 12 weeks prior to 
randomization. Subjects’ positive for latent TB per workup may be randomized to the trial if 
sufficient treatment has been initiated according to local routine clinical practice and will be 
maintained for the prescribed duration. Subjects positive for active TB per workup are not 
eligible for the study . Subjects negative for TB per workup (no signs of latent or active TB) 
may be randomized to the trial.

[COMPANY_001] Confidential Page 67
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Figure 6-1 Tuberculosis screening flowchart

[COMPANY_001] Confidential Page 68
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.2.6 Other baseline characteristics
Baseline characteristic data to be collected on all subjects include (all labs are central except 
where indicated): 
ECG, vital signs; hema tology ; clinical chemistry ; local urinal ysis; past medical history  record 
of HIV, hepatitis B or hepatitis C status;  PASI ; IGA mod 2011; cDL QI. 
A serum pregnancy  test will be performed for females of child bearing potential or of at lea st 
[ADDRESS_136971] eCRF page (visit specific and summary  pages). 
Information on drug dispensing, administration, accountability  will be collected in drug 
accountability  logs and other documents as appropriate. For drug administrations at home 
subject will record relevant information at home which will then be transcribe d at the 
corresponding documents at site including Dosage Administration Record eCRF page (see also 
Section 5.5).
Compliance will also be assessed and confirmed by [CONTACT_121957], preparation, administration and accountability .  
6.4 Efficacy
All efficacy  assessments should be performed prior to admin
istration of study  treatment. 
Qualified site personnel (efficacy  assessors) other than those treating the subjects, blinded to 
the allocation, will perform the efficacy  assessments.
There are two co-primary efficacy  variables in this study : PASI 75 respons e and IGA mod 2011 
0 or 1 response.
The following order should be applied when performing the efficacy  assessments during study 
visits:
Investigator’s Global Assessment (IGA mod 2011; scale from 0 –4)
Psoriasis Area and Severity  Index (PASI ; score from 0 – 72)
6.4.1 Investigator Global assessment (IGA  mod 2011)
An efficacy  assessor other than the investigator treating the subject will perform IGA mod 2011 
assessment as indicated in Table 6-3. It is recommended that the same assessor conducts the 
efficacy  assessment throughout the stud y whenever possible.
The IGA mod 2011 rating scale for overall psoriatic disease is 
shown in Table 6 -3below.
The IGA mod 2011 scale has been developed based on a previous version of the scale used in 
secukinumab phase II studies in collaboration with health authorities, in particular the FDA. 

[COMPANY_001] Confidential Page 69
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
The explanations/descriptions of the points on the scale have been improved to ensure 
appropriate differentiation between the points.
The IGA mod [ADDRESS_136972]’s disease 
state at the time of the assessments, and does not attempt acomparison with any of the subject’s 
previous disease states, whether at baseline or at a previous visit.
The IGA mod [ADDRESS_136973] clear- Normal to pi[INVESTIGATOR_108997]; no thickening; no to minimal focal scaling
2Mild-Pi[INVESTIGATOR_22767]; just detectable to mild thickening; predominantly fine scaling
3 Moderate -Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate 
thickening; moderate scaling
4 Severe - Bright to deep dark red coloration; severe thickening with hard edges; severe / coarse 
scaling covering almost all or all lesions
Based on this scale, a subject will be eligible to participate in the study  if the subject has an IGA 
mod [ADDRESS_136974] 3 points on the IGA mod 2011 scale 
compared to baseline. The IGA score will be recorded in the study -specific paper source form 
then will be entered into the eCRF at all visits with exception of Randomization visit when it 
will be also entered into the I RT to assess eligibility  based on IGA mod 2011 score.
6.4.2 Assessment of total body surface area (BSA ) and psoriasis area safety  
index (PASI)
The efficacy  assessor (other than the investigator treating the subject) will complete the PASI 
assessment as indicated in Table 6-1,Table 6 - 2. Whenever possible, the same assess or should 
perform this efficacy  assessment at all visits.
The total BSA affected by [CONTACT_109010]
-type psoriasis will be estimated from the percentages of areas 
affected, including head, trunk, upper limbs and lower limbs (see below for full details of the 
PASI  assessment). The following calculations will be done: Each reported percentage will be 
multiplied by [CONTACT_121958] (head = 0.1, trunk = 0.3, upper 
limbs = 0.2, lower limbs = 0.4). The resulting four percentages will be adde d up to estimate the 
total BSA affected b y plaque -type psoriasis.
A PASI  score (Fredriksson 1978, Weisman 2003, Gottlieb 2005 ) will be derived as indicated 
in Table 6-4. The head, trunk, upper limbs and lower limbs are assessed separatel y for erythema, 
thickening (plaque elevation, induration), and scaling (desquamation). The average degree of 
severit y of each sign in each of the four body  regions is assigned a score of 0-4. The area covered 
by [CONTACT_121959] a percentage of the total area of that particular 
body  region. Further practical details he lp the assessment:
The neck is assessed as part of the head.

[COMPANY_001] Confidential Page 70
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
The axillae and groin are assessed as part of the trunk.
The buttocks are assessed as part of the lower limbs.
When scoring the severity  of ery thema, scales should not be removed.
Table 6-4 PASI scoring sy stem 
Body region Ery thema (E) Thickeni ng (I)
(plaque 
elevation, 
induration)Scalin g (D)
(desquamation)Area score (A)
(based ontrue area %)*
Head (H)† 0=none 0=none 0=none 0 =no involvement
1=slight 1=slight 1=slight 1 =>0-<10%
2=moderate 2=moderate 2=moderate 2 =10-<30%
3=seve re 3=seve re 3=seve re 3 =30-<50%
4=very seve re 4=very seve re 4=very seve re 4 =50- < 70%
5 =70-<90%
6= 90 -100%
Trunk (T)‡ 0=none 0=none 0=none 0 =no involvement
1=slight 1=slight 1=slight 1 =>0-<10%
2=moderate 2=moderate 2=moderate 2 =10-<30%
3=seve re 3=seve re 3=seve re 3 =30-<50%
4=very seve re 4=very seve re 4=very seve re 4 =50- < 70%
5 =70-<90%
6= 90 -100%
Upper limbs ( U) 0=none 0=none 0=none 0 =no involvement
1=slight 1=slight 1=slight 1 =>0-<10%
2=modera te 2=modera te 2=modera te 2 =10-<30%
3=seve re 3=seve re 3=seve re 3 =30-<50%
4=very seve re 4=very seve re 4=very seve re 4 =50- < 70%
5 =70-<90%
6 =90-100%
Lower limb (L)§ 0= none 0=none 0=none 0 =no involvement
1=slight 1=slight 1=slight 1 =>0-<10%
2=modera te 2=modera te 2=modera te 2 =10-<30%
3=seve re 3=seve re 3=seve re 3 =30-<50%
4=very seve re 4=very seve re 4=very seve re 4 =50- < 70%
5 =70-<90%
6 =90-100%
*   Percentage (not score) of body region (not whole body) affected will be entered in the eCRF
† Neck is assessed as part of the Head (H) body region.
‡ Axillae and groin are assessed as part of the Trunk (T) body region.
§ Buttocks are assessed as part of the Lower limbs (L) body region.
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately  
10%, 20%, 30% and 40% of the body  surface area, respectively , the PASI score is calculated 
using the formula:
PASI =0.1 (EH+IH+DH)AH+0.2(EU+IU+DU)AU+0.3(ET+IT+DT)AT +0.4(EL+IL+DL)AL

[COMPANY_001] Confidential Page 71
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
The key s for the letters are provided in Table [ADDRESS_136975] and collecting the components, 
scoring signs and total regional area. The efficacy assessor/qualified site staff will record PASI 
data in the study -specific paper source 
worksheet at study  visits and subsequentl y, 
investigator/qualified site staff will enter the data into PASI  eCRF. 
Calculations based on collected PASI  components (e.g. total PASI score, BSA, PASI 75 
responder status- as applicable) will be done by [CONTACT_121952]/qualified site staff. These will 
also be entered in the PASI  source worksheet and PASI  eCRF as required.
At Visit 1 and Visit 2, the efficacy assessor/qualified site staff, after collecting the components 
of the PASI calculation, must calculate and verify  (as indicat ed previously ) the total PASI score 
and the total BSA.
Based on PASI, to be eligible, a subject must have a score of [ADDRESS_136976] 10% or more total BSA involved at the 
Randomization Visit.
Only  if the above eligibility  criteria and all other eligibility  criteria are fulfilled should site 
contact [CONTACT_121960].
At Visit 8 (Week 12), the efficacy  assessor/qualified site staff, after col lecting the components 
of the PASI calculation, must calculate (as indicated previously ) the total PASI  score. In 
addition the PASI  [ADDRESS_136977] be calculated. Subjects achieving ≥ 
75% improvement (reduction) in PASI  score compar ed to baseline (Randomization Visit) are 
defined as PASI 75 responders . Those achieving < 75% improvement are considered as PASI 
[ADDRESS_136978] is 
PASI  75 responder on PASI  75 non responder. 
Definitions of efficacy variables based on PA SI
The following definitions are used in this study  (see CHMP guidelines for psoriasis 
(CHMP/EWP/2454/02 2004)) :
PASI 50 response (partial response) : subjects achieving ≥ 50% improvement (reduction) in 
PASI  score compared to baseline are defined as PASI  50 responders
PASI 75 response : subjects achieving ≥ 75% improvem ent (reduction) in PASI  score compared 
to baseline are defined as PASI  75 responders
PASI 90 response : subjects achieving ≥ 90% improvement (reduction) in PASI  score compared 
to baseline are defined as PASI  90 responders
PASI 100 response / remission : comp lete clearing of psoriasis (PASI=0)

[COMPANY_001] Confidential Page 72
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.4.[ADDRESS_136979]’s body  area is affected by [CONTACT_90050], is considered acceptable by [CONTACT_19397] (CHMP guideline on the treatment of psoriasis -CHMP/EWP/2454/02 2004) to 
assess efficacy  in conjunction with I nvestigator’s Global Assessment  (IGA).
6.5 Safet y 
All blood draws and safety assessments should be done prior to study treatment administration. 
Appropriate safety  assessments (e.g., evaluation of AEs and SAEs including injection site 
reactions) should be repeated after the dose is administered.
During the COVID
-19 pandemic or simi lar major health care disruption that limits or prevents 
on-site study  visits, phone calls, virtual contacts (e.g. teleconsult), or visits by [CONTACT_121961] d protocol visit dates (or more frequently  if needed). This will be done for safety 
monitoring and discussion of thesubject´s health status until the subject can again visit the 
site. Case report forms (e.g. AEs, concomitant medications, procedures and non-drug therapi[INVESTIGATOR_014]) 
should be updated as appropriate.
6.5.1 Physical examination 
A physical examination, including general appearance, skin, neck, eyes, ears, nose, throat, lungs, 
heart, abdomen, back, lymph nodes, and extremities, and vascular and neurological systems 
will be performed as indicated in Table 6-1, Table 6-2. Inv estigator should pay special attention 
to any  signs or s ymptoms of potential skin or mucosal candida infections.
If indicated, based on medical history  and/or sy mptoms, additional exams will be performed at 
the discretion of the investigator.
If possible, assessments for an individual subject should be performed by  [CONTACT_121962] .
Information for all phy sical examinations must be included in the source documentation at the 
study  site. 
Significant findings that are present prior to the screening visit (Visit 1) must be 
included in the Medica l History  screen on the subject’s eCRF. Significant findings made after 

[COMPANY_001] Confidential Page 73
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
the start of study  (Visit 1) that meet the definition of an adverse event must be recorded on the 
Adverse Event screen of the subject’s eCRF.
 
 
 
 
 
 
 
 
6.5.3 Vital signs 
Vital signs (including blood pressure and pulse measurements) will be assessed at every 
scheduled visit as indicated in Table 6-1, Table 6-2. If possible, assessments should be 
performed b y the same study  site staff member throughout the study .
After the subject has been sitting for five minutes, with back supported and both feet placed on 
the floor, systolic and diastolic blood pressure will be measured twice (measurements 
separated b y 1 to 2 minutes) using a validated device, with a cuff that is appropriatel y sized for 
the 
subject’s arm circumference. The average of the two measurements will be entered on the 
Vital Signs eCRF.
Whether action needs to be taken to address notable vital signs will be decided by [CONTACT_1275]/qualified site staff, taking into account the overall status of the subject. No specific 
action is foreseen as part of the study  protocol. Notable values for vital signs are indicated in 
Appendix 1 , Table 13-1. 
6.5.4 Height and weight 
Height and body  weight will be measured at visits as in Table 6-1, Table 6-2. Height 
measurements (in indoor clothing, but without shoes, socks, hats or hair accessories interfering 
with assessment) will be made using a stadiometer that is calibrated on a regular basis. Height 
measurements will be performed twice and the reported height will be the mean of the 2 
measurements. 
If possible, body  weight assessments (in indoor clothing, but without shoes) should be 
performed b y the same study  site staff member and using the same scale throughout the study. 
The body  weight recorded at Randomization (Visit 2) will be used to categorize the subject 
population at randomization and placebo PASI 75 non -respo nders at Week 12 respectively , to 
receive the corresponding doses in the high dose and low dose secukinumab groups.

[COMPANY_001] Confidential Page 74
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.5.[ADDRESS_136980] at home to draw blood/ urine samples if needed to check safet y parameters.
Clinically  notable values for key laboratory  tests are defined in Section 
13, Appendix 1. For 
identification of pediatric a bnormal values for all parameters, the laboratory  manual must also 
be consulted.
Whether action needs to be taken to address notable laboratory  values will be decided by [CONTACT_1275], taking into account the overall status of the subject. No specific a ction is foreseen 
as part of the stud y protocol.
[IP_ADDRESS] Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential 
(neutrophils including bands, lymphocy tes, monocy tes, eosinophils, basophils) and platelet 
count will be meas ured at scheduled study  visits, as specified in Table 6 -
1, Table 6 -2.
[IP_ADDRESS] Clinical chemistry
Serum chemistry  will include urea or BUN, creatinine, total bilirubin, AST (SGOT), ALT 
(SGPT), GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, 
total protein, albumin, and uric acid.
Serum chemistry  will be measured at scheduled study  visits as specified in Table 6-1, Table 6 -
2. 
Estimated GFR
In addition estimated Glomerular Filtration Rate (eGFR) as per Schwartz et al ( Schwartz 2009) 
will be calculated 
and reported by [CONTACT_15622] , whenever a serum creatinine is 
performed.
The calculation is based on the following formula: 
eGFR (ml/min/1.73m2) = 0.413 x height (cm) / serum creatinine (mg/dl)
Height will be provided by  [CONTACT_121963].
For eGFR, baseline value for the decrease from baseline criterion will be calculated as the 
average of values prior to the first dose (i.e. screening and baseline values).

[COMPANY_001] Confidential Page 75
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Fasting glucose (conditional)
In case urine dipstick evalua tion shows new glucosuria ≥ 1+, a fasting blood sample must be 
collected and sent to central lab for glucose analy sis. More details can be found in Section 7.4. 
[IP_ADDRESS] Urinaly sis
Urine Dipstick (local) 
A mids tream urine sample (approx. 
30 mL) will be obtained, in order to avoid contamination 
with epi[INVESTIGATOR_107183], and allow proper assessments.
A semi -quantitative ‘dipstick’ evaluation for the following parameters will be performed: 
specific gravi ty, pH, glucose, protein, bilirubin, ketones, leukocytes and blood, micro albumin. 
Urinaly sis will be measured locall y at scheduled study visits as specified in Table 6 - 1, Table 6-
2.
Quantitative Urinaly sis (conditional) and Urine Microscopy  (conditional)
If the dipstick result is positive for protein, glucosuria and/or blood, a urine sample will be sent 
to central laboratory for microscopic anal ysiswhich will include WBC, RBC, crystals, casts as 
indicated in the renal safety  section ( Section 7.4). 
Furthermore, whenever eGFR decrease meets alert values as indicated in renal safety  section 
(Section 
7.4) a urine sample must be sent to the central laboratory  for quantitative urinal ysis. 
This analysis will include protein and creatinine to calculate the protein over creatinine ratio 
(PCR) and other p arameters like bilirubin, blood, color, glucose, ketones, leukocy tes, esterase, 
nitrite, pH, protein, specific gravit y, urobilinogen.
6.5.6 Electrocardiogram (ECG) 
A standard [ADDRESS_136981]’s source documentation. All ECGs must be performed on the ECG machines provided 
to the study  site.
All ECGs will be independently  reviewed by a central reader. Instructions for the collection and 
transmission of the ECGs to the independent reviewer will be provide d in the ECG investigator 
manual.
Even though there is no exclusion criterion specifically based on the ECG, the ECG performed 
at screening (Visit 1) must be reviewed for major abnormalities before dosing at the 
randomization visit. If the ECG findings areclinically  relevant and would prevent the subject 
from participating in the study  (taking into account the subject's overall status including medical 
history  and concomitant medications), the subject should not receive treatment and should exit 
the study .If a clinicall y relevant abnormality  is noted on the screening ECG it should be 
reported in the Medical History  eCRF. Clinically  relevant abnormalities noted after the 
screening ECG (Visit 1) should be recorded as AEs.

[COMPANY_001] Confidential Page 76
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.5.8 Pregnancy  and assessments of fertility  
Females of child- bearing potential are defined as all females physiologically  capable of 
becoming pregnant. This includes female pediatric patients who are menarchal or who become 

[COMPANY_001] Confidential Page 77
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
menarchal during the study . In this study  pregnancy  tests will be performed in female subjects 
who are menarchal or become menarchal during the study and/or are [ADDRESS_136982] should be considered in accordance with the local law and ethics.
All menarchal girls and their parents/caregivers should be informed about the potential risks of 
pregnancy  and the need to prevent pregnancy  during the study. It is important to be sensitive in 
introducing this issue, as understanding and comprehension of puberty , sexual activi ty, 
pregnancy  and contraception is influenced by [CONTACT_654], as well as factors such as precocit y, socio-
educational economic and familial background. These discussions with the patient and her 
parents/caregivers are therefore best performed by [CONTACT_121964]. 
These discussions should take into account the socio- economic, cultural factors and religious 
beliefs of the adolescent participant andher family . The investigator should also discuss the 
management of the pregnancy  test results with the patient and her parents/caregivers. The 
privacy  of the patient should be considered in accordance with the local law and ethics.
Additional pregnancy  tests may  be performed at the investigator’s discretion during the study . 
Patients becoming pregnant must be discontinued from study  drug. However, a patient may 
choose to remain in the study  should she become pregnant, and be followed in the treatment -
free follow -up epoch as described in Table [ADDRESS_136983] be informed of the need to prevent pregnancy , by [CONTACT_121965] a minimum of 16 weeks 
after stoppi[INVESTIGATOR_121893] (e.g. in EU 20 weeks). At a 
minimum, the acceptable effective contraception is:
Barrier methods of contraception: 
a.Male or female condom  with or without spermicide 
b.Cap, diaphragm or sponge with spermicide 
Use of established oral, injected or implanted hormona l methods of contraception , 
intrauterine device (IUD) or intrauterine s ystem (IUS)
The decision on the contraceptive method should be reviewed at least every  3 months to 
evaluate the individual need and compatibility  of the method chosen.

[COMPANY_001] Confidential Page 78
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
6.5.[ADDRESS_136984]’s health -related quality  of life (HRQoL) 
will be assessed b y Children’s Dermatology  Life Quality  Index (CDL QI).
The impact of Psoriatic Arthritis, on those subjects who have reported History  of Psoriatic 
Arthritis will be assessed by [CONTACT_29382]/c ustodian via the use of the childhood health 
assessment questionnaire, CHAQ©.
Sufficient time must be allowed for completion of both questionnaires. Questionnaires must be 
completed in a quiet environment.
Completed questionnaires will be reviewed and examined by [CONTACT_7893] (not the investigator 
or evaluator of the subject for the physician assessments), before the clinical examination, for 
responses that may indicate potential AEs or SAEs. If AEs or SAEs are confirmed then the 
events must be recorded as per instructions given in Section 7 of the protocol. Study  site staff 
should not encourage the subjects to change the responses reported in the completed 
questionnaire.
[IP_ADDRESS] Children’s Quality  of Life Index (CDLQI) 
The Children’s Dermatology  Life Qualit y Index (Lewis Jones and Finlay , 
1995) is a 10-item 
general dermatology  disability  index designed to assess health -relate d quality  of life in pediatric 
subjects aged [ADDRESS_136985] with the help of parent/custodian if and 
as needed. The site staff may help understand the questions, as necessary .The subject should 
be given sufficient space and time to complete the questionnaire. The stud y coordinator should 
check the questionnaire for completeness and encourage the subject to complete any missing 

[COMPANY_001] Confidential Page 79
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
responses before the clinical examination. Once su bjects reach [ADDRESS_136986] as indicated in Table 6 -1, Table 6 -
2.
During the COVID
-19 pandemic or similar major health care disruption that limits or prevents 
on-site study  visits, CDLQI questionnaire data may be collected remotely (e.g. via telephone 
interview of the subject) by [CONTACT_1746]. This will depend on local regulations, 
technical capabilities and following any applicable training in the required process. 
Documentation of the procedure should follow the vendor emergency  manual directives.
[IP_ADDRESS] Childhood Health A ssessment Questionnaire (CHA Q) for subjects with 
Psoriatic A rthritis
The childhood health assessment questionnaire CHAQ©(Singh et al 1994 ;Ruperto et al 2001 ), 
will be used to assess physical ability and functional status of patients as well as quality of life, 
for those children only who have reported History  of Psoriatic Arthritis. A representative 
example of the questionnaire is provided in Appendix 7 .
The disability  dimension consists of 20 multiple choice items concerning difficult y in 
performing eight common 
activities of daily  living; dressing and grooming, arising, eating, 
walking, reaching, personal hygiene, grippi[INVESTIGATOR_121894] “activities”. The person completing the 
questionnaire chooses from four response categories, ranging from ‘without any difficult y’ to 
‘unable to do’. 
The CHAQ©will be completed by a parent/custodian only if a validated version of the 
instrument is available in the language understandable to the parent at the visits indicated in 
Table 6 -
1. The same parent/custodian should preferably complete the questionnaire at all visits 
required per protocol. If patients turn 18 years of age during the study , the questionnaire will 
be completed together b
y the patient and the parent/custodian for the remaining visits.
[IP_ADDRESS].1 Parent’s or patient’s global assessment of patient’s overall well -being (VAS)
The parent’s or patient’s global assessment of patient’s overall well- being will be assessed on 
the VAS that is part of the CHAQ©. The VAS scale ranges from 0 -100 mm, from very  well (0
mm) to very  poor (100 mm).
Scores on the [ADDRESS_136987] millimeter from the left.
[IP_ADDRESS].2 Parent’s or patient’s assessment of pain (VAS)
The parent’s or patient’s assessment of pain will be assessed on the VAS that is part of the 
CHAQ©. The VAS scale ranges from 0 -100 mm, from no pain (0 mm) to very severe pain (100 
mm).
Scores on the [ADDRESS_136988] millimeter from the left.
6.6.2 Resource utilization 
Not applicable

[COMPANY_001] Confidential Page 80
Amended Protocol v04 (clean) Protocol No. C AIN457A2310

[COMPANY_001] Confidential Page 81
Amended Protocol v04 (clean) Protocol No. C AIN457A2310

[COMPANY_001] Confidential Page 82
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
7 Safety  monitoring 
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after prov iding written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive qu estioning of the patient 
at each visit or scheduled phone contact [CONTACT_61641] . Adverse events also may be detected 
when they are volunteered by [CONTACT_121966], laboratory test, or other assessments .
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms, 
they are considered clinically significant, 
they require therapy . 
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered tobe non-typi[INVESTIGATOR_18532]. Investigators have the responsibility  for managing the safet y of individual 
patient and identifying adverse events. Notable ranges for labs
 values are included in Appendix 
1.
Adverse events should be recorded in the Adverse 
Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  [CONTACT_6644].
the severit y grade 
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities

[COMPANY_001] Confidential Page 83
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
severe: prevents normal activities . 
its relationship to the
study  treatment (no/y es), or
investigational treatment (no/y es), or
the other stud y treatment (non -investigational) (no/y es), or
both or indistinguishable
Its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved should be reported.
whether it constitutes a serious adverse event (SAE -See Section 7.2 for definition of 
SAE)
action taken regarding [study /investigational] treatment (select as appropriate)
All adverse events should be treated appropriately . Treatment may include one or more ofthe 
following: 
no action taken (i.e. further observation only ) 
study  treatment dosage adjusted/temporarily  interrupted 
study  treatment permanently  discontinued due to this adverse event 
concomitant medication given 
non-drug therap y given 
patient hospi[INVESTIGATOR_057]/patient’s hospi[INVESTIGATOR_18533] 
its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  drug, the interventions 
required to treat it, and the outcome.
Worsening of psoriasis in this study  is evaluated via 
the use of PASI , IGA mod 2011 and cDLQI 
assessments and is not expected to be captured as an AE in the eCRF. Exceptions include cases 
when a) a new type of psoriasis is diagnosed e.g. guttate psoriasis) or b) the worsening of 
psoriasis is so severe that a qualitatively  different status is reached.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator’s Brochure (IB) or will be communi cated between IB updates in the 
form of Investigator Notifications. This information will be included in the patient informed 
consent and should be discussed with the patient during the stud y as needed.
The investigator should also instruct each patient to report any new adverse event (bey ond the 
protocol observation period) that the patient, or the patient’s personal physician, believes might 
reasonabl y be related to study  treatment. This information should be recorded in the 
investigator’s source document s; however, if the AE meets the criteria of an SAE, it must be 
reported to [COMPANY_001].

[COMPANY_001] Confidential Page 84
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
7.2 Serious adverse events 
7.2.1 Definition of SA E 
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medi cal conditions(s) which meets any one of the following 
criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_27588], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this includes)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, i.e. defined as an event that jeopardizes the patient or may  require 
medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if more severe (see Annex I V, ICH-E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as impor tant medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_18534]. Examples of such events 
are intensive treatment in an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_121895] (see Annex IV, ICH-E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual 
reporting to Drug Safety  and Epi[INVESTIGATOR_623]  (DS&E) as per section 7.2.2.
7.2.[ADDRESS_136989] dose was taken or until 30 days after 

[COMPANY_001] Confidential Page 85
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
the last stud y visit (whichever is later) must be reported to [COMPANY_001] w ithin [ADDRESS_136990] dose was taken or until End of 
study  visit (whichever is later) must be recorded in the AE eCRF. SAEs beyond that date will 
only be recorded in the [COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_121896].
Any SAEs experienced after the [ADDRESS_136991] 
dose was taken (whichever is later) , should only be reported to [COMPANY_001] if the investigator 
suspects a causal relationship to stud y treatment. 
Recurrent epi[INVESTIGATOR_1841], complications, or progression of the initial SAE must be reported as follow -
up to the original epi[INVESTIGATOR_1865], regardless of when the event occurs. This report must be submitted 
within 24 hours of the investigator receiving the follow -up information. An SAE that is 
considered completel y unrelated to a previously  reported one should be reported separately  as 
a new event.
Information about all SAEs (either initial or follow up information) is collected and recorded 
in English on the paper Serious Adverse Event Report Form or the electronic Serious Adverse 
Event Form within the Oracle Clinical/Remote Data Capture (OC/RDC) system (where 
available). The Investigator must assess the relationship to each specific component of the study 
treatment (if the stud y treatment consists of several components). 
SAEs (initial and follow -up) that are recorded on the paper SAE form should be faxed within 
[ADDRESS_136992] be 
kept with the case report form documentation at the study  site. Follow -up information should 
be provided using a new paper SAE Report Form stating that this is a follow -up to a previousl y 
reported SAE   
SAEs (initial and follow -up) that are recorded electronically in the OC/RDC sy stem should be 
entered, saved and e -signed within 24 hours of awareness of the SAE or changes to an existing 
SAE. These data will automatically  be submitted to [COMPANY_001] Drug Safety  &  E pi[INVESTIGATOR_121897] i nvestigator signature [INVESTIGATOR_1660] [ADDRESS_136993]. 
Follow -up information provided should describe whether the event has resolved or continues, 
if and how it was treated, whether the treatment code was broken or not and whether the pat ient 
continued or withdrew from study  participation. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously documented in the Investi gator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the investigational treatment a Drug Safet y and 
Epi[INVESTIGATOR_121898]. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same investigational 
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 

[COMPANY_001] Confidential Page 86
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
committees in accordance with EU Guidance 2011/C 172/[ADDRESS_136994] reaches adulthood ( ≥18 y ears of 
age) this procedure no longer needs to be followed. However, if a subject is followed upfor a 
speci fic event with liver monitoring procedures while turning 18, follow -up should continue 
until the event stabilizes or resolves.
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study :
Liver labora tory triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 14-1 in Appendix 2for complete definitions of liver laboratory  triggers 
and liver events. 
Every  liver laboratory  trigger or liver event as defined in Table 14-1 of Appendix 2should be 
followed up by [CONTACT_121967]. 
Detailed information is outlined in Table 14
-2of Appendix 2 .
For the liver laboratory  trigger:
Repeating the LFT within the next week to confirm elevation.
These LFT repeats should be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
patient. Repeats laboratory  should then be performed at central laboratory as soon as possible. 
If a liver event is subsequently  reported, any local LFTs previousl y conducted that are 
associated with this event should be reported on the L iver CRF pages.
If the elevation is confirmed, close observation of the patient will be initiated, including 
consideration of treatment interruption if deemed appropriate.
For the liver events:
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug if appropriate
Hospi[INVESTIGATOR_18539]
A causalit y assessment of the liver event via exclusion of alt ernative causes (e.g., disease, 
co-medications)
An investigation of the liver event which needs to be followed until resolution. 
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 

[COMPANY_001] Confidential Page 87
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
the procedures performed should be recorded on appropriate CRF pages, includi ng the liver 
event overview CRF pages.
7.[ADDRESS_136995] reaches adulthood ( ≥18 y ears of 
age) this procedure no longer needs to be followed. However, if a subject is followed upfor a 
specific event with renal monitoring procedures while turning 18, follow -up should continue 
until the event stabilizes or resolves. 
The following two categories of renal adverse events have to be considered during the course 
of the study :
1. Serum event:
confirmed decrease in estimated glomerular filtration rate (eGFR) of  ≥ 25% compared to 
baseline during normal hydration status as estimated by  [CONTACT_121968] :               
eGFR  (ml/min/1.73m2) = 0.413 x height (cm) / serum creatinine (mg/dl)
2. Urine event: New onset ( ≥1+) proteinuria, hematuria or glucosuria 
new onset of proteinuria should be confirmed b y urinary  protein creatinine ratio 
Every  renal laboratory  trigger or renal event as defined in Table 7-1should be followed up by 
[CONTACT_121969] s
ummarized below. 

[COMPANY_001] Confidential Page 88
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Table 7-1 Specific Renal A lert Criteria and A ctions
Serum Event
Estimated GFR decrease
25 –<50% compared to baseline and eGFR 
<90mL/min/1.73m2Confirm125%-<50% decrease and eGFR <90mL/min/1.73m2 
after [ADDRESS_136996] morning urine collection.
Then do some frequent monitoring (preferably weekly) until 
event resolves2or stabilizes3. 
If event does not resolve or stabilize consider c onsulting 
nephrologist and/or drug interruption.
Acute Kidney Injury: Serum Estimated GFR 
decrease 50 % compared to baselineFollow up within [ADDRESS_136997] and/or drug 
interruption. 
Urine Event
New dipstick proteinuria ≥ 1+ Confirm1value after 24 -48h, if possible.
If dipstick value confirmed: 
a) perform1urinary protein creatinine ratio (PC R) within [ADDRESS_136998] morning urine collection.
b) perform urine microscopy and evaluate .
If PCR > 0. 2g/gand/or urine microscopy has f indings (e.g. 
crystals, casts, dysmorphic RBC, leukocytes) consider 
consulting nephrologist or drug interruption or discontinuation.
New dipstick glucosuria ≥ 1+ not due to 
diabetesConfirm value after 24 -48h, if possible .
If it persists: 
a) perform, blood glucose (fasting).
b) perform urinary protein/creatinine ratio. 
If PCR ratio > 0.2 g/g and blood glucose normal consider 
consulting nephrologist and /or drug interruption or 
discontinuation .
New dipstick hematuria ≥ 1+ not due to 
trauma or mensesConfirm1value after 24 -48h, if possible .
If it persists:
a) perform1urinary protein creatinine ratio (PCR) within 2-[ADDRESS_136999] morning urine collection. 
b) perform urine microscopy and evaluate.
If PCR > 0.2 g/gand /or urine microscopy has findings (e.g. 
crystals, casts , dysmorphic RBC, leukocytes) consider 
consulting nephrologist or drug interruption or discontinuation.
For all renal events:
Urine samples for testing for renal monitoring, and particularly those for the PCR ratio determination, must be 
collected at the first morning void.
Document contributing factors in the CRF: co-medication, other co -morbid conditions, and additional 
diagnostic procedures performed 
1Investigator and subject may decide to perform urinary PCR already with the first repeat
Monitor patient regularly (frequency at investigator’s discretion) until either: 
2Event resolution: estimated GFR within 20% of baseline and >90mL/min/1.73m2or PCR < 0. 2g/g (<22.6
mg/mmol). 
3Event stabilization: estimated GFR within 20% of baseline OR >90mL/min/1.73m2or PCR < 0. 3 g/g (<34 
mg/mmol).

[COMPANY_001] Confidential Page 89
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
7.[ADDRESS_137000] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded on the Pharmacovigilance Pregnancy  Form and reported by [CONTACT_50105] y and Epi[INVESTIGATOR_18540]. Pregnancy 
follow-up should be recorded on the same form and should include an assessment of the 
possible relationship to the study  treatment.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
8 Data revie w and database management 
8.1 Site monitoring 
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and CRFs with the investigators and their staff. During 
the study , [COMPANY_001] employ s several methods of ensuring protocol and GCP compliance and the 
quality /integrity  of the sites’ data. The field monitor will visit the site to check the completeness 
of patient records, the accuracy  of entries on the (e)CRFs, the adherence to the protocol and to 
Good Clinical Practice, the progress of enrollment, and to ensure that study  treatment is being 
stored, dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the field monitor during these visits. Continu ous remote monitoring of each 
site’s data may be performed by a centralized [COMPANY_001] CRA organization,   Additionally , a 
central analy tics organization may analyse data & identify  risks & trends for site operational 
parameters, and provide reports to Novar tis Clinical Teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, labora tory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The investigator must also keep the original informed consent form signed b y the 
patient (a signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of 
SAEs, and of data that will be used for all primary  variables. Additional checks of the 
consistency  of the source data with the CRFs are performed according to the study -specific 
monitoring plan. No information in source documents about the identity  of the patients will be 
disclosed.

[COMPANY_001] Confidential Page 90
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
8.2 Data collection 
Designated investigator staff will enter the data required by [CONTACT_109051]/RDC 
system. Designated investigator site staff will not be given access to the s ystem until they have 
been trained. 
Automatic validation procedures within the system check for data discrepancies during and 
after data entry  and, by [CONTACT_105273], allow the data to be confi rmed 
or corrected online by [CONTACT_105274]. The Investigator must certify  that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copi[INVESTIGATOR_105196]. 
8.[ADDRESS_137001], which employ s the Anatomical Therapeutic Chemical classification system. 
Concomitant procedures, non-drug therapi[INVESTIGATOR_121899] (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
[COMPANY_001] (or a designated CRO).
ECG readings will be processed centrall y and the results will be sent electronically to [COMPANY_001] 
(ora designated CRO).
Randomization codes and data about all study  drug(s) dispensed to the patient and all dosage 
changes will be tracked using an Interactive Response Technology  (IRT). The system will be 
supplied by a
 vendor, who will also manage the datab ase. The database will be sent 
electronically  to [COMPANY_001] (or a designated CRO).
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  The 
code break functionality  will remain available until study  shut down or upon request of [COMPANY_001]. 
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis. Any 
changes to the database after that time can only be made after written agreement by [CONTACT_18660].
Subjects/custodians will use an electronic tablet device to enter PRO data (CDLQI) as indicated 
in Section 6.6.1. The data will be transmitted by [CONTACT_779], processed centrally b y the vendor and 
the results will be sent electronicall y to [COMPANY_001] (or designee). A tablet device Site Manual will 
be provide d for instructions related to tablet data entry . There are no other source data for this 
questionnaire, 
the data are entered directly  in the tablet. In case of a technical issue  related to 
the tablet use during a study  visit with a CDLQI assessment and which cannot be resolved 

[COMPANY_001] Confidential Page 91
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
during the visit, a paper CDL QI questionnaire can be used as an emergency  back-up solution. 
Data captured via the paper questionnaire will be retrieved and managed by [CONTACT_121970] ’s standard procedure.   
For CHAQ©the parents/custodians will complete the questionnaire. Questionnaire will be 
completed together with patient if the patient is 18 years of age or older. The completed 
questionnaire will be transmitted to the vendor. Thedata will then be processed centrally  by [CONTACT_121971] (or designee).
 
 
 
 
 
8.4 Data Monitoring Committee 
An external data monitoring committee (DMC) will be appointed to monitor the safet y and 
efficacy  of the stud y subjects.
The safety  and efficacy  data from the first 80 adolescent subjects will be evaluated before 
children ages 6 to < 12 years can be enrolled. Further to that, safety  and efficacy  data will be 
reviewed b y the DMC during the stud y, as described in the Secukinumab DMC Charter. 
Details regarding the DMC process, responsibilities and membership will be available, as 
needed, in the rel evant Secukinumab DMC charter. 
8.5 Adjudication Committee 
Not required.
9 Data analy sis 
Treatment groups for analy ses will include as shown in Table 9-1. 
Table 9-1 Treatment groups for analy ses
Weight category Up to Week 12
Low dose 
secukinumabHigh dose 
secukinumabPlacebo Etanercept
(max 50m g per 
dose)
<25kg 75mg 75mg X 0.8mg/kg
25-<50kg 75mg 150m g X 0.8mg/kg
>50kg 150m g 300m g X 0.8mg/kg
Weight 
categoryWeek 12 -52

[COMPANY_001] Confidential Page 92
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Low dose 
secukinumabHigh dose 
secukinumabPlacebo to Low 
dose 
secukinumabPlacebo to High 
dose 
secukinumabEtanercept 
(max 50mg per 
dose)
<25kg 75mg 75mg 75mg 75mg 0.8mg/kg
25-<50kg 75mg 150mg 75mg 150mg 0.8mg/kg
>50kg 150mg 300mg 150mg 300mg 0.8mg/kg
Weight 
categoryEntire Study
Low dose 
secukinumabHigh dose 
secukinumabPlacebo Etanercept
(max 50mg 
per dose)Any Low 
dose 
secukinumabAny High
dose 
secukinumab
<25kg 75mg 75mg x 0.8mg/kg 75mg 75mg
25-<50kg 75mg 150mg x 0.8mg/kg 75mg 150mg
>50kg 150mg 300mg x 0.8mg/kg 150mg 300mg
Summary  statistics for continuous variables will include n, mean, standard deviation, minimum, 
lower quartile, 
median, upper quartile, maximum. Summary  statistics for discrete variables will 
be presented in contingency  tables and will include absolute and relative frequencies.
If not otherwise specified, p-values will be presented as one -sided for hypothesis testings and 
as two- sided for other analy sis. Two- sided 95% confidence intervals will be display ed.
9.1 Analysis sets 
The following anal ysis sets will be used in this trial:
Randomized set: The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis-
randomized subjects (mis-randomized in IRT) will be excluded 
from the randomized set. (Mis-randomized subjects are defined as cases where IRT contacts
were made by [CONTACT_37292] y or inappropriatel y prior to confirmation of the 
subject’s final randomization eligibili ty and double -blind treatment was not administered to the 
subject).
Full analysis set (FAS) : The FAS will be comprised of all subjects from the randomized set to 
whom study  treatment has been assigned. Following the intent -to-treat principle, subjects will
be analyzed according to the treatment assigned to at randomization. If the actual stratum is 
different to the assigned stratum in I RT, the actual stratum will be used in anal yses.
Safety set: The safety  set includes all subjects who took at least one dose of study  treatment
during the treatment epoch. Subjects will be analyzed according to treatment received.
9.[ADDRESS_137002] demographics and other baseline characteristics 
Demographics and baseline characteristics
Summary  statistics will be presented for continuous demographic and baseline characteristics
variables for each treatment group and for all subjects in the randomized set. The number and
percentage of subjects 
in each category  will be presented for categorical variables for each
treatment group and all s ubjects.

[COMPANY_001] Confidential Page 93
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Medical history
Any condition entered as medical history  or current medical conditions at baseline will be coded 
using the MedDRA dictionary . They  will be summarized by [CONTACT_121972] . Summaries for psoriasis specific medical history  will be 
provided as well.
9.[ADDRESS_137003] certain thresholds 
(e.g. any exposure, ≥ 1 week, ≥ 2 weeks, ≥ 3 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be display ed.
Prior and concomitant treatment
Prior and concomitant treatments will be summarized by [CONTACT_121973]. 
Prior treatments are defined as treatments taken and stopped prior to first dose of study 
treatment. An ytreatment given at least once between the day of first dose of randomized stud y 
treatment and the last day of stud y visit will be a concomitant treatment, including those which 
were started pre -baseline and continued into the treatment epoch.
Treatments will be presented in alphabetical order, by [CONTACT_121974] 
(ATC) codes and grouped by [CONTACT_121975]. Tables will also show the overall number 
and percentage of subjects receiving at least one treatment of a particular ATC code and at least 
one treatment in a particular anatomical main group. Psoriasis specific prior treatments will be 
presented as well.
In addition, non- drug therapi[INVESTIGATOR_6545].
9.4 Analysis of the primary  variable(s)
This section will detail the statistic al analy sis of the primary  endpoints. Details of thehypothesis
testing strategy  including primary  and secondary  endpoints to handle multiplicity  are provided 
inSection 9.5.1.
9.4.1 Variable(s)
The co-primary  efficacy  variables are PASI 75 response at Week 12 and IGA 0 or 1 response
at Week 12. The analy sis of the co
-primary  variables will be based on the FAS.
9.4.2 Statistical model, hypothesis, and method of analy sis
The statistical hy potheses for PASI  75 response at Week 12 and IGA 0 or 1 response at Week 
12 being tested isthat secukinumab (low orhigh dose) is not superior to placebo in the 
proportion of subjects with PASI  75 and IGA 0 or 1 response at Week 12 .

[COMPANY_001] Confidential Page 94
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Let   denote the proportion of PASI 75responders at Week 12 for treatment group j and   
denote the proportion of IGA 0 or 1 responders at Week 12 for treatment group j, j=0, 1, 2,
where
0 corresponds to placebo,
1 corresponds to secukinumab low dose ,
2 corresponds to secukinumab high dose .
The following h ypotheses will be tested
H : p –p ≤0 versus H  : p –p >0,
H : p –p ≤0 versus H   : p –p >0,
H : r –r ≤0 versus H   : r –r >0,
H : r –r ≤0 versus H   : r –r >0.
In other words:
H : Secukinumab low dose is not superior to placebo with respect to PASI 75 response at
Week 12
H : secukinumab high dose is not superior to placebo with respect to PASI 75 response at
Week 12
H : secukinumab low dose is not superior to placebo with respect to IGA 0 or 1 response at 
Week 12
H : secukinumab high dose is not superior to placebo with respect to IGA [ADDRESS_137004] logistic regression with all 4 treatment groups 
(including etanercept); baseline body weight, age stratum and baseline PASI  score as 
explanatory  variables. Odds ratios will be computed for comparisons of secukinumab dose
regimens versus placebo utilizing the logistic regression model fitted. Confidence intervals for 
risk difference will be derived based on the exact method. 
9.4.3 Handling of missing values/censoring/discontinuations
The following imputation methods will apply  to the missing data for analy sis up to Week52 
including primary  W12 analy sis:
Response variables based on PASI score and IGA mod 2011 categories will be imputed 
with multiple imputations (MI) method as primary  imputation method. Multiple 
imputation (MI) is a simulation based approach where missing values are replaced by 
[CONTACT_121976], creating multiple completed data sets. These completed 
data sets can then be analy zed using standard methods. Within this analy sis the PASI 
score or IGA mod 2011 categories will be imputed and response variable s will be 
derived based on the imputed scores. In the multiple imputation analysis the response 
status will be imputed based on the individual treatment arm information.  

[COMPANY_001] Confidential Page 95
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
(Pure) Non-responder imputation will be used as a sensitivity  method: Missing values
with respect to response variables based on PASI score and IGA mod [ADDRESS_137005]-baseline missing will be imputed with non-
response.
The following imputation methods will apply  to the missing data for analysis 
of the long term 
 
 
9.4.4 Supportive analy ses 
Sensitivity  analy ses will be performed as follow s:
PASI  [ADDRESS_137006] logistic 
regression model with treatment group , baseline body weight stratum , age stratum and 
baseline PASI as effects with pure non-responder imputations for missing values. 
Primary  anal ysis will also be evaluated on the subset of adolescents
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables 
The secondary  variable in testing strategy  isthe PASI  90 response of subjects with severe 
chronic plaque -type psoriasis at Week 12 (for superiority  comparison of secukinumab doses 
versus placebo)
.The PASI  [ADDRESS_137007]  as the primary  variables. 
The secondary  efficacy  variable PASI 90 at Week 12, willbe analyzed using the FAS unless 
otherwise specified.
Testing strategy
The family -wise type I error will be set to α=2.5% (one-sided). The graphical approach of Bretz 
(Bretz et al 2009) for sequentially  rejective testing procedures is used to illustrate the 
hierarchical testing strategy . The procedure allows the type I error rate associated with a rejected 
hypothesis to be reallocated according to a set of pre-
specified rules. The hypotheses associated 
to the primary  and secondary  variables are as below.
Co-primary  variables : 
H1to H 4(see Section 9.4.2)
Secondary  variable:
H5: secukinumab low dose is not superior to placebo with respect to PASI 90 response at
Week 1 2

[COMPANY_001] Confidential Page 96
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
H6: secukinumab high dose is not superior to placebo with respect to PASI 90response at
Week 1
2
The graphical approach of (Bretz 2009 ) for sequentially  rejective testing proced ures is used to 
illustrate the testing strategy in Figure 9 -1.
Figure 9 -1 Testing strategy
One- sided p - values will be derived. The family -wise error will be set to α=2.5% (one-sided). 
The hypotheses are mapped into two sets (H1, H3and H5) or (H2, H4and H6) such that 
hypotheses 
within a set correspond to the same secukinumab (AIN457) dose regimen. In 
essence, the t ype-I-error probability  will be equally split for both sets of h ypotheses and within 
each set the h ypothesis are tested sequentially as follows:
Within each pair, of hypotheses (H1or H3) and (H2or H4), each hypothesis is tested at α/2 (one-
sided). Only  if both hy potheses of a pair are rejected, the testing sequence will continue.
In the next step of the sequence, the null hypotheses corresponding to the PASI  90comparison 
of secukinumab (AIN457) versus placebo istested. H 5and H 6will be tested at α/2 (one-sided).
If all hy potheses within a set referring to a secukinumab dose regimen have been rejected, i.e., 
either (H1, H3andH5) or (H2, H4andH6), the corresponding typeIerror probability  can be 
passed on to 
theother set of hypotheses, and if needed, hypotheses can be retested at a higher 
significance level.
9.5.[ADDRESS_137008] method.  
For PASI  75, PASI 90, PASI  100 and IGA 0 or 1 response at each visit, each secukinumab dose 
regimen will be compared to placebo (up to Week 12 only) by [CONTACT_121977] 97
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
regression with treatment group, baseline body weight stratum , age stratum and baseline PASI 
score as explanatory  variables.
For PASI  75, PASI  90 and IGA 0 or 1 response the placebo- adjusted response rates including 
95% confidence interval (exact method) will be derived by [CONTACT_121978] 12. Similarly, 
estimates for the difference in response rates for secukinumab minus  will be deriv ed 
over time.
Figures will also be provided. 
PASI score over time
Summary  statistics will be provided for absolute PASI  scores as well as for percent change from 
baseline b y visit and treatment group. Figures will also be provided.
IGA mod 2011 score over time
Summary  statistics for the IGA mod 2011 score over time will be presented by [CONTACT_121979].
 
 
 
 
 
9.5.3 Safety  variables 
All safet y evaluations will be performed on the Safety set.
Adverse events
Treatment emergent adverse events (events started after the first dose of study  treatment and 
within [ADDRESS_137009] study 

[COMPANY_001] Confidential Page 98
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
treatment) will be summarized. Only  primary  paths within MedDRA will be considered for 
adverse event reporting. 
AEs will be summarized by [CONTACT_1601], for each treatment group, the number and percentage
of subjects having any AE, having an AE in each primary  system organ class and having each
individual AE (preferred term). Summaries wil l also be presented for AEs by [CONTACT_11370] y and for
study  treatment related AEs. If a subject reported more than one adverse event with the same
preferred term, the adverse event with the greatest severit y will be presented. If a subject
reported more than one adverse event within the same primary  system organ class, the subject
will be counted only once with the greatest severity  at the system organ class level, where
applicable.
These summaries will be presented separately for induction period and entire trea tment period.
Confidence intervals for relative frequencies will be derived as well according to the exact 
method.
Separate summaries will be provided for death, serious adverse event, other significant adverse 
events leading to discontinuation and adverse events leading to dose adjustment (including 
study  treatment discontinuation).
A graphical display  of relative frequencies within sy stem organ classes will be presented.
In supplementary anal yses, for selected adverse events exposure (or observation) time adjusted 
analyses in terms of incidence rate will be provided for the entire treatment period .
Laboratory  data
The summary  of laboratory  evaluations will be presented for three groups of laboratory  tests
(hematology , serum chemistry  and urinal ysis). Descr iptive summary  statistics for the change
from baseline to each study  visit will be presented. These descriptive summaries will be
presented b y test group, laboratory test and treatment group. Change from baseline will only be 
summarized for subjects with b oth baseline and post baseline.
For each parameter, the maximum change from baseline within each study  period will be
analyzed analogousl y.
In addition, shift tables will be provided for all lab parameters to compare a subject ’s baseline 
laboratory  evaluat ion relative to the most extreme post-baseline laboratory  test value. Shift 
tables with respect to Common Toxicity  grade Criteria (CTC) and normal ranges will be 
provided b y laboratory test and treatment group . 
Incidence rates of notable abnormalities (se e Appendix 1 ) will be presented.
Vital signs
Analy sis of the vital sign measurements using summary  statistics for the change from baseline
for each post- baseline visit will be performed. These descriptive summaries will be presented

[COMPANY_001] Confidential Page 99
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
by [CONTACT_37297]. Change from baseline will only  be summarized for subjects
with both baseline and post -baseline values.
All information collected will be listed by [CONTACT_121980] (see Appendix 1) will
be flagged.
ECG
Summary  statistics will be presented for ECG variables by  [CONTACT_3232].
Grow th and weight gain
Growth and weight gain will be summarized descriptively .
9.5.4 Resource utilization 
Not Applicable.
9.5.5 Health -related Quality of Life
Children’s Dermatology  Quality of Life Index (CDLQI)
The CDLQI measures functiona l disability  of subjects with dermatological disorders that are
lessthan 18 years of age and had been utilized as a relevant clinical measure in atopic dermatitis, 
as well as other dermatitis clinical trials. The CDLQ I is a simple, validated, self-adminis
tered
10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, 
leisure, school or holidays, personal relationships, sleep andtreatment). The questions are based 
on the preceding week to permit accurate recall. For the CDLQI, each question will be answered 
on a 4 -point L ikert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the 
total score of each of the six dimensions as well as the total score over all items. The higher the
score, the more qua lity of life is impaired.
For each of the seven scores the percentage change from baseline will be derived. Summary
statistics will be provided for absolute values as well as for the percentage change by  [CONTACT_121979]
.TheCDLQI 0 or 1 achievement will be analy zed by [CONTACT_121981].
Childhood Health A ssessment Questionnaire (CHA Q©)
Changes in health- related quality  of life for subjects with history  of psoriatic arthritis will be 
measured using CHAQ©.
Descriptive statistics will be used to summarize patient responses on the CHAQ©Questionnaire 
by [CONTACT_3148], total score and by  [CONTACT_121982]. 
For parent’s or patients global assessment of patient’s overall well- being and of pain (VAS 
score) summary  statistics for the observ ed values and the change/percent change from baseline 
will be provided by  [CONTACT_765].

[COMPANY_001] Confidential Page 100
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
9.5.8 Biomarkers 
Not applicable
9.5.9 PK/PD 
Not applicable
9.[ADDRESS_137010] 80 adolescents complete 24 weeks of 
treatment. The key efficacy  and safety  data will be reviewed by [CONTACT_121983] y concerns are observed with the study  treatments. Enrollment of the 
pediatric population aged 6 to less than 12 years will begin only when the safety  and efficacy 
evaluation is satisfactory based on the DMC’s recommendation. 
An additional interim analysis,will be conducted once sufficient safet y  
data have been collected. This analy sis, aligned with the efficacy  extrapolation principle, is
expected to provide the basis for a submission package to health authorities (HA), with the 
intent to allow earlier availability  of secukinumab to pediatric patient s, in countries which 

[COMPANY_001] Confidential Page 101
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
accept a submission of clinical data with use of extrapolation method ology .This anal ysis may
be performed before all subjects have reached the primary  endpoint .It is expected that data 
from at least approximately [ADDRESS_137011] of a Ba yesian full extrapolation approach using adult efficac y 
data along with available pediatric , safet y, and efficacy  data to support a submission to 
Health Authorities for plaque type psoriasis in a pediatric population of ages 6 to 18 y ears. This 
analysis will use a Bayesian meta -analytic-prediction (MAP) approach (Neuenschwander 2010 ) 
to demonstrate the consistency  of efficacy  responses between adults and pediatric population. 
The MAP approach is based on a Bayesian random -effects meta -analysis and provides a 
prediction of adult efficacy  response rates in a new trial. The prediction will take into account 
uncertaint y due to sample size and due to between -trial heterogeneit y.
The observed pediatric response rates at Week 12 for PASI  75, PASI 90 and IGA 0/1 in this 
study  will be checked for consistency  with predicted response rates based on [COMPANY_001] adult 
studies (CAIN457A2302 ,CAIN457A2303 ,CAIN457A2308 and CAIN457A2309) using a 
predictive check method.
Since the planned hypothesis will not be tested at this interim, the ty pe-I error probability  will 
not be adjusted for this interim and full alpha will be kept for the hypothesis test in the final 
analysis. 
A full analysis of all data collected up to Week 24, inc luding primary endpoint at Week [ADDRESS_137012] completed either the Week 24 visit or the premature 
treatment discontinuation visit (i.e., EOI (Week 12 visit) for subjects discontinuing during 
induction epoch or EOM (Week 52 vi sit) for subjects discontinuing during the maintenance 
epoch visit. Data from subjects who have completed the treatment -free follow -up visits up to 
this time point (after premature discontinuation from the induction or the maintenance epoch) 
will also be i ncluded in this analy sis.
Another full analy sis of all data collected up to Week 52, including primary  endpoint at Week 
[ADDRESS_137013] completed either the Week 52 visit or the premature 
treatment discontinuation visit (i.e., EOI (Week 12 visit) for subjects discontinuing during 
induction epoch or EOM (Week 52 visit) for subjects discontinuing during the maintenance 
epoch visit. Data from subjects who have completed the treatment -free follow -up visits up to 
this time point (after premature discontinuation from the induction or the maintenance epoch) 
will also be included in this analy sis. 
Efficacy  and safet y data collected during the extension treatment epoch (until the end of study) 
may bereported yearly in separate reports.
9.7 Sample size calculation
Approximately  160 pediatric subjects from 6 to less than 18 years of age, with 2 subgroups: 6 
to less than 12 y ears of age, and 12 to less than 18 y ears of age.  
Stratification is planned for age (<12 years, >=12 years) and weight (<25kg, 25-<50kg 
and >50kg )
. It will be targeted to have at least 30 subjects in the <12 years subgroup at a 
minimum. Enrollment of children aged 6 to less than 12 years will proceed after efficacy  and 

[COMPANY_001] Confidential Page 102
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
safet y data for approximately  80 (approximately  40 treated with AIN) enrolled adolescents 
(aged 12 to less than 18 years) treated for [ADDRESS_137014] to theco-
primary endpoints (PASI 75 response and IGA 0 or 1 response at Week 12), the type-I-error
will be split to 1.25% one -sided for each comparison. With 40subjects per group and assuming 
a response rate of 10% for PASI 75 response and IGA 0 or 1 response in the placebo group, the 
power to show a response rate of 65% for PASI 75 response and 45% for IGA 0 response in the 
secukinumab groups based on Fisher’s exact test (nQuery  Advisor 7.0, two group Fisher’s -exact 
test of equal proportions) is approximately  99% for PASI  75 response and approximately  88% 
for IGA mod 2011 
0 or 1 response. For the secondary  endpoint of PASI  90response at week 
12, assuming a response rate of 8% in the placebo group, the power to show a significant 
difference between a secukinumab dose and placebo, assuming a response rate of 39% in the 
secukinumab groups based on Fisher’s exact test (nQuery  Advisor 7.0, two group Fisher’s -exact 
test of equal proportions) is approximately 82% for PASI  90response. The assumed response 
rates for secukinumab are based on the confirmatory  efficacy  in severe patients in the adult 
phase III program. At Week 12, PASI 75 response rates of 11% and PASI 90 response rates of 
7% have been reported in the placebo group in Paller et al (2008) for children and adolescents 
aged 4 -17 years.  
10 Ethical considerations 
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guideli nes for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese Ministry  of 
Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of 
Helsinki.
10.2 Informed consent procedures 
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally  acceptable representative(s) of the patient. 
In cases where the patient’s representative gives consent, the patient should be informed about 
the study  to the extent possible given his/her understanding. If the patient is capable of doing 
so, he/she should indicate assent by [CONTACT_15063] a separate assent form. Informed consent must be obtained before conducting an y 
study -specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the patient source documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory  requirements and is conside red 
appropriate for this study . Any changes to the proposed consent form suggested by [CONTACT_121984] 103
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
investigator must be agreed to by [CONTACT_109060]/ IEC, and a copy of 
the approved version must be provided to the [COMPANY_001] monitor after IRB/IE C approval.
In pediatric patients (< 18 years of age) parental permission and, whenever possible, child assent 
is needed instead of the procedure for informed consent used for research involving adults. In 
general, one or both parents or a guardian must beprovided with the information ordinaril y 
required for informed consent, so that they may decide whether to allow the child to participate, 
and children capable of assent must also express their willingness to participate. These forms 
will be submitted for IRB/IEC/REB approval.
Women of child bearing potential should be informed that taking the study  treatment may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhe re to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
 
 
 
 
In the event that [COMPANY_001] wants to perform testing on the samples that are not described in this 
protocol, additional Institutional Review Board and/or Ethics Committee approval will be 
obtained.
During the COVID -[ADDRESS_137015] the informed 
consent discussion remotely  (e.g. telephone, 
videoconference). Guidance issued by  [CONTACT_121985] y docu mented (e.g. the presence of an impartial witness, 
sign/dating separate ICFs or assent forms by [CONTACT_121986]/ guardian and person obtaining 
informed consent, etc).
In case Home Nursing (other than study  treatment administration) is implemented during the 
COVID -[ADDRESS_137016] be used in addition to the main I CF.
10.3 Responsibilities of the investigator and IRB/IEC 
Before initiating a trial, the investigator/institution should obtain approval/favorable opi[INVESTIGATOR_50074]/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment procedures 
(e.g., advertisements) and any other written information to be provided to patients. Prior to 
study  start, the investigator is required to sign a protocol signature [CONTACT_5389]/her 
agreement to conduct the study  in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
[COMPANY_001] monitors, auditors, [COMPANY_001] Qualit y Assurance representatives, designated agents of 

[COMPANY_001] Confidential Page 104
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
[COMPANY_001], IRBs/IECs, and regulatory  authorities as required. If an inspec tion of the clinical site 
is requested by a regulatory  authorit y, the investigator must inform [COMPANY_001] immediately  that 
this request has been made.
10.4 Publication of study  protocol and results 
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this trial will be either submitted for publication 
and/or posted in a publicly  accessible da tabase of clinical trial results.
[ADDRESS_137017] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and health authorities, where required, it cannot be implemented. 
All significant protocol deviations will be recorded and reported in the CSR.
11.[ADDRESS_137018] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an apparent immediate hazard 
to patients may be implemented immediatel y provided the Health A uthorities are subsequentl y 
notified by [CONTACT_6670]/ IEC is notified. Notwithstanding the 
need for approval of formal protocol amendments, the investigator is expected to take any 
immediate action required for the safety of an y patient included in this study, even if this action 
represents a deviation from the protocol. In such cases, the reporting requirements identified in 
Section [ADDRESS_137019]
Augustin M, Reich K, Glaeske G et al (2010). Co-morbidity  and Age -related Prevalence of 
Psoriasis: Analy sis of Health I nsurance Data in [LOCATION_013] , Acta Derm Venereol 2010; 90: 
147–151.
Beattie PE and Lewis -Jones MS (20
06). A comparative study  of impairment of quality  of life 
in children with skin disease and children with other chronic childhood diseases; Br J 
Dermatol 2006 Jul; 155(1), 145–151.
Benoit S, Hamm H, (2007) Childhood psoriasis. Clin Dermatol , 25, 555 –562

[COMPANY_001] Confidential Page 105
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
 
Bretz F, Maurer W, Brannath W, Posch M (2009). A graphical approach to sequentially  
rejective multiple test procedures. Statist. Med.; 28: 586 -604.
Burden A D (1999); Management of psoriasis in childhood; CED, 24, 341 –345.
Committee for medicinal products for human use (CHMP), European Medicines Agency  for 
the Evaluation of Medicines for Human Use. (2004) Guideline on clinical investigation of 
medicinal products indicated for the treatment of psoriasis. CHMP/EWP/2454/02 corr 
393document. L ondon, [LOCATION_006].
Comans- Bitter WM et al (1997); Immunophenotypi[INVESTIGATOR_121900] l ymphocy tes in childhood; J 
Pediatr Volume 130, Number 3, 388. 
De Jager MEA et al (2009); Epi[INVESTIGATOR_121901]: 
A survey  among medical professionals, Journal of Dermatological Treatment. 2009; 20:254 –
258.
De Jager MEA, De Jong EM, Van de Kerkhof PCM et al (2010); Efficacy  and safet y of 
treatments for childhood psoriasis: A sy stematic literature review, J Am Acad Dermatol 2010; 
62:1013-30.
Dohert y SD, Van Voohees A, Lebwohl MG (2008) National psoriasis foundation consensus 
statement on screening for latent tuberculosis infection in patients with psoriasis treated with 
systemic and biologic agents. J. Am. Acad. Dermatol; 59 (2): 209 – 217.
Farber EM, Nall ML , (1999); Childhood Psoriasis; Cutis 1999 Nov; 64(5): 309 -14.
Feld LG and Corey  H (2007) Hy pertension in childhood. Pediatr in Rev.; 28: 283-98.
Fredriksson T, Pettersson U (1978) Severe psoriasis – oral therap y with a new retinoid. 
Dermatologica; 157:238 –44.
Gelfand JM, Weinstein R, Porter SB et al (2005). Prevalence and Treatment of Psoriasis in the 
[LOCATION_008]: A Population based Study ; Arch Dermatol 2005;
141:1537-1541
Gottlieb A, Griffiths CEM, Ho VC, et al (2005) Efficacy  and tolerability  of oral pi[INVESTIGATOR_121902]: a double -blind, 
multicenter, randomized dose -finding trial. Br J Dermatol; 15 2:1219 -27.
Griffiths CEM, Barker JNWN (2007) Pathogenesis and clinical features of psoriasis. Lancet; 
370: 263 – 271.
Kimball AB et al (2012) Risks of developi[INVESTIGATOR_121903], J Am Acad Dermatol 2012; 67:651-7.
Kokubu T, et al (2008); Immunolocalization of IL- 17A, IL -17B, and Their Receptors in
Chondrocytes during Fracture Healing; J Histochem Cy tochem. Volume 56(2): 89–95.
Landells I, Paller AS, Pariser D et al (2010); Efficacy  and safet y of etanercept in child ren and 
adolescents aged ≥8 years with severe plaque psoriasis; Eur J Dermatol 2010; 20 (3): 323 -8.
Langley  RG, Elewski BE, L ebwohl M et al (2014) Secukinumab in plaque psoriasis- Results 
of two phase three trials. N Engl J Med. Jul 24; 371(4): 326-38
Lewi s-Jones MS, Finlay  AY. The Children's Dermatology  Life Quality  Index (CDL QI): 
initial validation and practical use. Br J Dermatol 1995; 132: 942-949.

[COMPANY_001] Confidential Page 106
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Luu M, and Cordoro KM (2013). The Evolving Role of Biologics in the Treatment of 
Pediatric Psoriasis. Skin Therap y Lett. 2013 Feb; 18(2) 1 - 7
Manuel O, Kumar D (2008) QuantiFERON -TB Gold assay  for the diagnosis of latent 
tuberculosis infection. Expert Rev Diagn; 8(3): 247-56.
Neuenschwander B, Capkun -Niggli G, Branson M, Spi[INVESTIGATOR_59898] (2010) Summarizin g 
historical information on controls in clinical trials. Clin Trials; 7(1): 5 –18.
Newcombe RG (1998) Two
-sided confidence intervals for the single proportion: comparison 
of seven methods. Statist. Med.; 17: 857-872.
Paller AS et al (2008) Etanercept Treatm ent for Children and Adolescents with Plaque 
Psoriasis. N Engl J Med 2008; 358:241-51.
Paller AS et al (2013) Association of Pediatric Psoriasis Severity with Excess and Central 
Adiposity  JAMA Dermatol. 2013; 149(2):166 -176.
Pariser DM, Bagel J, Gelfand JM et al (2007) National Psoriasis Foundation Clinical 
Consensus on Disease Severity . Arch Dermatol.; 143: 239 -242.
Ruperto et al (2001) Cross- cultural adaptation and psy chometric evaluation of the Childhood 
Health Assessment Questionnaire (CHAQ©) and the Ch
ild Health Questionnaire (CHQ) in 32 
countries. Review of the general methodology . Clin Exp Rheumatol; 19 (Suppl 23):S1 -S9.
Schwartz GJ, Munoz A, Schnei MF et al (2009). New equations to estimate GFR in children 
with CKD. J Am Soc Nephrol ; 20:629-637.
Silverberg NB (2009); Pediatric psoriasis; Ther Clin Risk Manag 2009;5 849–856.
.
Singh et al (1994) Measurement of Health Status in children with juvenile Rheumatoid 
Arthritis. Arthritis and Rheum; Vol 37, 12:1761 -
1769.
Tollefson et al (2010) Incidence of psoriasis in children: a population based study. J Am Acad 
Dermatol. 2010 Jun; 62(6):979-87.
Van Weelden H, Baart de la faille H, Young E and Van der leun J C (1990); Comparison of 
Narrow -band UV -B Phototherap y and PUVA Photo chemotherap y in the Treatment of 
Psoriasis; Acta Derm Ycnereol (Stockh) 1990; 70: 212 -215.
Weisman S, Pollack CR, Gottschalk RW (2003) Psoriasis disease severity  measures: 
comparing efficacy  of treatments for severe psori asis. J Dermatolog Treat; 14: 158-165.
Wu JJ et al (2011) L ow prevalence of psoriasis among children and adolescents in a large 
multiethnic cohort in southern [LOCATION_004]. J Am Acad Dermatol 2011; 65: 957-64.
Zappel K, Sterry  W, Blume -Peytavi U (2004) Therapy options for psoriasis in childhood and 
adolescence. JDDG; 2004. 2:329 – 342.

[COMPANY_001] Confidential Page 107
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
13 Appendix 1: Clinically  notable laboratory  values and vital 
signs 
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests and vital sign parameters. 
Unless otherwise indicated (e.g. liver and renal safet y monitoring procedure, Section 7.3 and 
Section 7.4 respecti vely) no specific action is pre-defined within this protocol to respond to 
specific abnormal laboratory  values, as it will be decided by  [CONTACT_121987] & which 
specific action needs to be taken to respond to any abnormal values, taking into accou nt the 
overall status of the subject.
Laboratory  values
Newl y occurring selected notable laboratory  abnormalities in pediatric patients at the time of 
the assessment:
Biochemistry  and Urinaly sis
Alanine transaminase (ALT)(SGPT): 
Upper Limit of Normal (ULN )
≥3 x UL N
≥5 x UL N
≥8 x UL N
≥10 x UL N
Aspartate transaminase (AST) (SGOT): 
>ULN
≥3 x UL N
≥5 x UL N
≥8 x UL N
≥10 x UL N
Total Bilirubin (TBL)
>ULN, 
≥1.5xUL N, 
≥ 2xUL N
ALP 
>ULN
≥1.5xUL N, 
≥2xUL N, 
≥3x UL N 
≥5xUL N
ALT and/or AST >3x- , 5x-, 10x UL N accompanied by  [CONTACT_121988] >2xULN
ALT or AST >3x ULN and TBL >2x- , and ALP >[ADDRESS_137020].
ALP >3x ULN and TBL >2x UL N

[COMPANY_001] Confidential Page 108
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Gamma -Glutam yltransferase (GGT): 
>ULN
≥3 x UL N
≥5 x UL N
Renal function
For the parameters related to renal function (e.g. eGFR according to Schwartz, urine protein, 
urine blood, glucosuria) the instructions provided in the renal safety  monitoring section must 
be followed ( Section 7.4 ). 
Hematology
Hemoglobin: ≥ 20 g/L decrease from baseline, 
or < 85 g/L for < 16 years of age
< 100 g/L for ≥ 16 y ears of age
Absolute neutrophils:
Grade 1: <LLN – 1.5 x 10E9/L
Grade 2: <1.5 – 1.0 x 10E9/L
Grade 3: <1.0 – 0.5 x 10E9/L
Grade 4: <0.5 x 10E9/L
Criteria based on CTC grades for platelet count:
Grade 1: <LLN – 75.0 x 10E9/L
Grade 2: <75.0 – 50.0 x 10E9/L
Grade 3: <50.0 – 25.0 x 10E9/L
Grade 4: <25.0 x 10E9/L
Criteria based on CTC grades for WBC:
G1:<LLN –3.0 x10E9/L
G2:<3.0 – 2.0 x10E9/L
G3:<2.0 – 1.0 x10E9/L
G4: <1.0 x10E9/L
Absolute Ly mphocy tes: < LLN 
Absolute Eosinophils: ≥ 1.[ADDRESS_137021]
Absolute Eosinophils: ≥0.45 x 109/L  
Vital Signs
The following notable criteria will be used for systolic and diastolic BP and pulse. The age 
indicated is the age at the time of the visit.

[COMPANY_001] Confidential Page 109
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Table 13-1 Notable Pediatric ranges for vital signs*
Age Systolic BP Diastolic BP Pulse (BPM)
6 yrs 91-125 53-84 60-130
7 yrs 92-126 55-86 60-130
8 yrs 94-127 56-88 60-130
9 yrs 95-129 57-89 60-110
10 yrs 97-130 58-90 60-110
11 yrs 99-132 59-90 60-110
12 yrs 101-135 59-91 60-110
13 yrs 104-137 60-91 60-110
14 yrs 106-140 60-92 60-110
15 yrs 107-142 61-93 60-110
16 yrs 108-145 63-94 60-110
17 yrs 108-147 64-97 60-100
18 yrs - - 60-100
Source: http://www.who.int/childgrowth/standards
*values outside the provided ranges are considered notable
The Recommendations for the dimensions of Blood Pressure Cuff Bladders are noted in the 
following table.
Table 13-2 Recommended Dimensions for Blood Pressure Cuff Bladders
` Width [cm ] Length [cm] Maximum Arm 
Circumference [cm]*
Newborn 4 8 10
Infant 6 12 15
Child 9 18 22
Small adult 10 24 26
Adult 13 30 34
Large adult 16 38 44
*calculated so that the bladder can encircle even the largest arm by  [CONTACT_2669] 80%
Source: Feld and Corey H (2007) : Hypertension in childhood, Pediatric in Review 28: 283- 98

[COMPANY_001] Confidential Page 110
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
14 Appendix 2: Liver event and Laborator y trigger Definitions 
and Follo w-up Requirements
Table 14-1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY TRIGGERS [ADDRESS_137022] < ALT / AST [ADDRESS_137023]
1.[ADDRESS_137024] < TBL [ADDRESS_137025]
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
TBL > 2 × ULN [mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, 
abdominal pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity * 
Table 14-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law 
caseaDiscontinue the study drug immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
ALT or AST
> 8 × ULN Discontinue the study drug immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study drug immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -up 
monitoring
If elevation persists for more than 2 
weeks , discontinue the study drug
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)

[COMPANY_001] Confidential Page 111
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
Criteria Actions required Follow -up monitoring
> 3 × ULN 
accompanied by 
[CONTACT_18688]Discontinue the study drug immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 to ≤ 5 × ULN 
(subject is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the subjectInvestigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the 
study drug immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
Test for hemolysis (e.g., reticulocytes, 
haptoglobin, unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN
(subject is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the subject Investigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
Jaundice Discontinue the study drug immediately
Hospi[INVESTIGATOR_27556]
Establish causality
Comple te liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
Any AE potentially 
indicative of a liver 
toxicity*Consider study drug interruption or 
discontinuation 
Hospi[INVESTIGATOR_6549]
Establish causality
Complete liver CRFInvestigator discretion
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified live r neoplasms
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a 
maximum of 6 months, (4) liver transplantation, and (5) death.

[COMPANY_001] Confidential Page 112
Amended Protocol v04 (clean) Protocol No. C AIN457A2310

[COMPANY_001] Confidential Page 113
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
16 Appendix 4: Weight and recommended blood volumes 
European Medicines Agency  (EMA) recommendations for trial related blood loss (including 
any losses in the maneuver) in pediatric populations are that no more than 3% of total blood 
volume should be taken during a four week period and not more than 1% of total blood volume 
at a single time -point. At a total blood volume estimated at 80 to 90ml p er kilogram (kg) bod y 
weight, this equates to 2.4mL  to 2.7mL blood per kg body  weight during a four week period, 
or 0.8mL  to 0.9mL blood per kg at any  one time. 
These recommended volumes must not be exceeded for an y patient. Please use the information 
below to ensure that the recommended volumes are adhered to.
Table 16-1 Total blood volume, 1% and 3% of total blood volume by  [CONTACT_121906] 85mL per kg total blood volume
Weight (Kg) Total Blood Volume* 
(mL)1% Blood Volume (mL)** 3% Blood Volume (mL)**
5 425 4 12
10 850 8 24
15 1275 12 36
20 1700 17 51
25 2125 21 63
30 2550 25 75
35 2975 29 87
40 3400 34 102
45 3825 38 114
50 4250 42 126
55 4675 46 138
60 5100 51 103
65 5525 55 165
70 5950 59 177
75 6375 63 186
80 6800 68 204
*all blood volumes are rounded down 

[COMPANY_001] Confidential Page 114
Amended Protocol v04 (clean) Protocol No. C AIN457A2310

[COMPANY_001] Confidential Page 115
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
18 Appendix 6:  CDLQI questionnaire
CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX
The aim of this questionnaire is to measure how much your skin problem has affected you 
OVER THE LAST WEEK.  Please tick one box for each question.
1.Over the last week, how itchy , "scratchy" , Very  much □
sore or painful has y our skin been? Quite a lot □
Only  a little □
Not at all □
2.Over the last week, how embarrassed Very  much □
or self-conscious , upset or sadhave you Quite a lot □
been because of your skin? Only  a little □
Not at all □
3.Over the last week, how much has your Very  much □
skin affected your friendships ? Quite a lot □
Only  a little □
Not at all □
4.Over the last week, how much have you changed Very  much □
or worn different or special
clothes/shoes Quite a lot □
because of your skin? Only a little □
Not at all □
5.Over the last week, how much has your Very  much □
skin trouble affected going out , playing, Quite a lot □
or doing hobbies ? Only  a little □
Not at all □
6.Over the last week, how much have you Very  much □

[COMPANY_001] Confidential Page 116
Amended Protocol v04 (clean) Protocol No. C AIN457A2310
avoided swimming or other sports because Quite a lot □
of your skin trouble? Only  a little □
Not at all □
7.Last week , If school time : Over the Prevented school □ 
last week, how much did Very  muc h □
Was it school time?   your skin problem affect y our Quite a lot □
school work ? Only  a little □
OR Not at all □
was it holiday time ?   If holiday time : How much Very  much □
over the last week, has your Quite a lot □
skin problem interfered with Only  a little □
enjoy ment of the holiday ? Not at all □
8.Over the last week, how much trouble Very  much □
have you had because of your skin with Quite a lot □
other people 
calling you names , teasing, Only  alittle □
bullying , asking questions or avoiding you ? Not at all □
9. Over the last week, how much has your sleep Very  much □
been affected b y your skin problem? Quite a lot □
Only  a little □
Not at all □
10.Over the last week, how much of a Very  much □
problem has the treatment for your Quite a lot □
skin been? Only  a little □
Not at all □
Please check that you have answered EVERY question. Thank you

[COMPANY_001] Confidential Page 117
Amended Protocol v04 (clean) Protocol No. CAIN457A2310
19 Appendix 7: CHAQ Questionnaire
1990 Original version by [CONTACT_121989] G et al. 1998 Cross-cultural adapted version by [CONTACT_121990] P, Murray 
KJ, Nugent J for PRINTO
1 CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE
2
In this section we are interested in learning how your child's illness affects his/her ability to function in daily life. Pleas e feel free to 
add any comments on the back of this page. In the following questions, please tick the one response which best describes your 
child's usual activities OVER THE PAST WEEK . ONLY NOTE THOSE DIFFICULTIES OR LIMITATIONS WHICH 
ARE DUE TO ILLNESS . If most children at your child's age are not expected to do a certain activity, please mark it as "Not 
Applicable". For example, if your child has difficulty in doing a certain activity or is unable to do it because he/she is too 
young but not because he/she is RESTRICTED BY [CONTACT_121991], please mark it as "NOT Applicable".
3 Without 
ANY 
DifficultyWith SOME 
DifficultyWith MUCH 
DifficultyUNABLE 
To doNot 
Applicable
4 DRESSING & PERSONAL CARE
5Is your child able to: 
6- Dress, including tying shoelaces and doing buttons?  
7- Shampoo his/her hair?  
8- Remove socks?  
9- Cut fingernails?  
10 GETTING UP
11Is your child able to:
12- Stand up from a low chair or floor?  
13- Get in and out of bed or stand up in a cot?  
14 EATING
15Is your child able to:
16- Cut his/her own meat?  
17- Lift up a cup or glass to mouth?  
18- Open a new cereal box?  
19 WALKING
20Is your child able to:
21- Walk outside on flat ground?  
22- Climb up five steps?  
23 * Please tick any AIDS or DEVICES that your child usually uses for any of the above activities:
24- Walking stick - Devices used for dressing (button hook, zip pull, long-
handled shoe horn, etc.)
25- Walking frame - Built up pencil or special utensils 
26- Crutches - Special or built up chair 
27- Wheelchair - Other (Specify:_____________________________) 
28 * Please tick any categories for which your child usually needs help from another person BECAUSE OF ILLNESS:
29- Dressing and personal care - Eating 
30- Getting up - Walking 
[COMPANY_001] Confidential Page 118
Amended Protocol v04 (clean) Protocol No. CAIN457A2310
31 Without 
ANY 
DifficultyWith SOME 
DifficultyWith MUCH 
DifficultyUNABLE 
To doNot 
Applicable
32 HYGIENE
33Is your child able to:
34- Wash and dry entire body?  
35- Take a bath (get in and out of bath)?  
36- Get on and off the toilet or potty?  
37- Brush teeth?  
38- Comb/brush hair?  
39 REACH
40Is your child able to:
41- Reach and get down a heavy object such as a large game or 
books from just above his/her head? 
42- Bend down to pi[INVESTIGATOR_121904] a pi[INVESTIGATOR_121905]? 
43- Pull on a jumper over his/her head?  
44- Turn neck to look back over shoulder?  
45 GRIP
46Is your child able to:
47- Write or scribble with pen or pencil?  
48- Open car doors?  
49- Open jars which have been previously opened?  
50- Turn taps on and off?  
51- Push open a door when he/s he has to turn a door knob?  
52 ACTIVITIES
53Is your child able to:
54- Run errands and shop?  
55- Get in and out of a car or toy car or school bus?  
56- Ride bike or tricycle?  
57- Do household chores (e.g. wash dishes, take out rubbish, 
hoovering, ga rdening, make bed, clean room)? 
58- Run and play?  
59 * Please tick any AIDS or DEVICES that your child usually uses for any of the above activities:
60- Raised toilet seat - Bathrail 
61- Bath seat - Long-handled appliances for reach 
62- Jar opener (for jars previously opened) - Long-handled appliances in bathroom 
63 * Please tick any categories for which your child usually needs help from another person BECAUSE OF ILLNESS:
64- Hygiene - Grippi[INVESTIGATOR_36123] 
65- Reach - Errands and chores 
66PAIN:  We are also interested in learning whether or not your child has been affected by [CONTACT_121992]. 
How much pain do you think your child has had because of his/her illness IN THE PAST WEEK?
Place a mark on the line below, to indicate the severity of the pain
67      No pain   0                                                                                                                     100 Very severe pain
68GENERAL EVALUATION:  Considering all the ways that arthritis affects you r child, rate how he/she is doing by [CONTACT_1299] a single 
mark on the line below.
69    Very well 0                                                                                                                     100 Very poor